rabeprazole has been researched along with Esophageal Reflux in 245 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This systematic review and network meta-analysis aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis." | 9.22 | Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. ( Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T, 2022) |
| "Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 9.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
| " The aim of this study was to examine the associations between sleep disturbances and refractory gastroesophageal reflux disease (GERD) symptoms in patients receiving once daily proton pump inhibitors (PPI) and the efficacy of twice-daily rabeprazole treatment." | 9.17 | Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment. ( Arakawa, T; Ashida, K; Fujiwara, Y; Habu, Y; Higuchi, K; Kusano, M, 2013) |
| "The pharmacokinetics of rabeprazole after a single oral dose and once-daily administration for 5 consecutive days was characterized in children 1 to 11 years old with gastroesophageal reflux disease (GERD)." | 9.15 | Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease. ( Doose, DR; Gonzalez, MD; Haddad, I; Leitz, GJ; Mulberg, AE; Rusch, S; Solanki, B; Zannikos, PN, 2011) |
| "To determine if the 4-week efficacy of rabeprazole 20 mg for resolving heartburn and regurgitation symptoms is non-inferior to esomeprazole 40 mg or 20 mg." | 9.14 | Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 9.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs." | 9.14 | Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. ( Delemos, B; Fass, R; Kao, R; Lu, Y; Nazareno, L; Xiang, J, 2010) |
| "To investigate the longitudinal changes in quality of life (QoL) for gastroesophageal reflux disease (GERD) treated with 52-week rabeprazole over a period of 2-3 years." | 9.14 | [Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment]. ( Hou, XH; Ke, MY; Liu, XH; Luo, JY; Song, ZQ; Yang, XL; Yuan, YZ, 2009) |
| "To study and document the efficacy and tolerability of rabeprazole and domperidone in the treatment of patients suffering from gastro-oesophageal reflux disease (GERD), an open, prospective, non-comparative study was carried out among 50 adult patients of either sex attending gastroenterology OPD of a leading, tertiary-care teaching hospital in Mumbai with the clinical diagnosis of GERD." | 9.13 | Rabeprazole plus domperidone: the answer for gastro-oesophageal reflux disease. ( Dabholkar, P; Sawant, P; Shahani, S, 2008) |
| " The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis." | 9.12 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. ( Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M, 2006) |
| "Rabeprazole and pantoprazole are both used for symptomatic treatment of gastro-oesophageal reflux disease (GERD)." | 9.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly." | 9.12 | Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. ( Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007) |
| "To study the acid exposure characteristic of the subtypes of non-erosive gastroesophageal reflux disease (NERD) and discuss the value of rabeprazole in its diagnosis." | 9.12 | [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole]. ( Fan, YH; Lü, B; Zhan, LX; Zhang, L, 2007) |
| "To compare the efficacy and safety of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease (GERD)." | 9.12 | Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. ( Pai, N; Pai, V, 2007) |
| "This study was conducted to characterize the pharmacokinetic and safety profile of rabeprazole sodium tablets in children and adolescents with gastroesophageal reflux disease (GERD)." | 9.12 | Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. ( James, L; Kao, R; Lomax, K; Reyes, J; Varughese, S; Walson, P, 2007) |
| "To evaluate continuous therapy (COT) and on-demand therapy (ODT) with rabeprazole 20 mg for maintenance in uninvestigated gastroesophageal reflux disease (GERD)." | 9.12 | Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. ( Camacho, F; Dinniwell, J; Horbay, GL; Husein-Bhabha, FA; Morgan, DG; O'Mahony, MF; O'Mahony, WF; Roy, J, 2007) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 9.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 9.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| "In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD)." | 9.11 | Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. ( Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E, 2005) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease." | 9.11 | Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. ( Johanson, J; Jokubaitis, L; Kahrilas, PJ; Mao, L; Miner, P; Sloan, S, 2005) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 9.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease." | 9.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 9.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease." | 9.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
| "To evaluate the efficacy and tolerability of rabeprazole 10 mg and 20 mg versus placebo for the prevention of endoscopically demonstrable relapse in patients previously diagnosed with erosive or ulcerative gastro-oesophageal reflux disease (GORD) who had no oesophageal erosions or ulcerations at study entry." | 9.09 | Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. ( Birbara, C; Breiter, J; Hahne, W; Perdomo, C, 2000) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 9.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 9.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| "The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD)." | 8.81 | Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. ( Caro, JJ; Salas, M; Ward, A, 2001) |
| "Rabeprazole sodium is a proton pump inhibitor used for the treatment of gastroesophageal reflux disease (GERD)." | 7.80 | Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years. ( Green, B; Kimko, H; Mannaert, E; McLeay, SC; Thyssen, A; Treem, W, 2014) |
| "The plasma concentration of rabeprazole in patients treated for gastroesophageal reflux disease (GERD) has not been reported, although the concentration in healthy volunteers has been reported previously." | 7.74 | Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation. ( Matsushita, HO; Yamano, HO; Yanagiwara, S, 2008) |
| "Results of the first week of treatment with rabeprazole in Hp+ and Hp- patients with gastroesophageal reflux disease (GERD) were compared in a large prospective open-label, multicenter, cohort study in general and specialized practices." | 7.73 | Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? ( Bergmans, P; de Boer, W; de Wit, N; Geldof, H; Hazelhoff, B; Smout, A; Tytgat, G, 2006) |
| "From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma." | 7.72 | A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. ( Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H, 2003) |
| " However, long-term use of PPIs can cause gut microbiome (GM) disturbances." | 7.11 | Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole. ( Li, Q; Li, Y; Liu, W; Lu, NH; Xiao, Q; Xie, Y; Xu, T; Yang, N; Zhang, H; Zheng, L; Zhou, X; Zuo, K, 2022) |
| " Both drugs were well tolerated, and the adverse event incidence profile was low." | 7.11 | Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease. ( Abdo-Francis, JM; Cabrera-Álvarez, G; Martínez-Torres, H; Remes-Troche, JM, 2022) |
| "Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment." | 6.82 | Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. ( Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016) |
| "However, during the second week, GERD-related NCCP had a higher positive PPI test (n = 13, 81%) than non GERD-related NCCP (n = 7, 27%) (P = 0." | 6.74 | Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. ( Kim, JH; Kim, JJ; Rhee, JC; Rhee, PL; Sinn, DH; Son, HJ, 2009) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 6.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| "Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being." | 6.71 | Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003) |
| " These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 6.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | 6.71 | On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| "Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg." | 6.71 | Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. ( Ang, TL; Chua, TS; Fock, KM; Ng, TM; Tan, YL; Teo, EK, 2005) |
| "Both rabeprazole doses were significantly superior to placebo in preventing relapse of heartburn frequency and improving patient quality of life." | 6.71 | Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| "Both rabeprazole doses were significantly superior to the placebo with respect to time to the first 24-h heartburn-free interval (2." | 6.70 | Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. ( Filippone, J; Jokubaitis, L; Miner, P; Orr, W; Sloan, S, 2002) |
| "Rabeprazole 20 mg in two different dosing schedules is as effective as omeprazole 20 mg QD with regard to efficacy and tolerability in patients with erosive GERD." | 6.69 | Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. ( Cohen, G; Delchier, JC; Humphries, TJ, 2000) |
| "Rabeprazole 20 mg/d was superior to rabeprazole 10 mg/d in preventing endoscopic relapse of erosive GERD, but that the two dosages were equivalent in symptomatic relief over 1 year." | 6.49 | Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis. ( Lan, Y; Wang, H; Xia, XM; Xu, SM; Zhu, HD, 2013) |
| "Gastroesophageal reflux disease (GERD) is associated with several symptoms, such as heartburn, belching, and regurgitation, which arise from esophageal exposure to gastric acid." | 6.42 | Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. ( Sloan, S, 2003) |
| "Gastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality." | 6.42 | Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. ( Thjodleifsson, B, 2004) |
| "Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD." | 6.42 | Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. ( Goh, KL; Lim, PW, 2004) |
| "Rabeprazole treatment significantly decreased both the FSSG and the PSQI score." | 5.36 | Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole. ( Arakawa, T; Fujiwara, Y; Hayakawa, T; Kaji, M; Kohata, Y; Machida, H; Nebiki, H; Sasaki, E; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamasaki, T, 2010) |
| "Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries." | 5.34 | Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. ( Chiba, T; Fujiwara, Y; Furuta, T; Habu, Y; Hongo, M; Ito, M; Kinoshita, Y; Koike, T; Miwa, H; Nagahara, A; Sasaki, M; Wada, T, 2007) |
| "Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs." | 5.33 | Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. ( Giannini, EG; Savarino, V; Testa, R, 2006) |
| "Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole." | 5.31 | Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. ( Bhattacharjya, A; Damiano, AM; Johanson, JF; Jokubaitis, L; Murthy, A; Siddique, R, 2002) |
| "This systematic review and network meta-analysis aimed to assess the relative efficacy of vonoprazan and proton pump inhibitors (PPIs) on early heartburn symptom resolution in patients with erosive esophagitis." | 5.22 | Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis. ( Deguchi, H; Fernandez, J; Fujimori, I; Igarashi, A; Nakano, H; Oshima, T, 2022) |
| "The addition of IM to rabeprazole significantly improves gastroesophageal reflux disease symptoms and the quality of the lives of patients with NERD grade N." | 5.20 | Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study. ( Igarashi, M; Imai, J; Koike, J; Masui, A; Matsushima, M; Mine, T; Nakamura, J; Suzuki, T; Tsuda, S; Tsukune, Y; Uchida, T; Yuhara, H, 2015) |
| ": The efficacy and safety of rabeprazole, a proton pump inhibitor, were studied in infants with gastroesophageal reflux disease (GERD)." | 5.19 | Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD. ( Hoffman, D; Hu, P; Hussain, S; Kierkus, J; Lekich, R; Sloan, S; Treem, W, 2014) |
| "The aim of the present study was to evaluate 24-week maintenance of efficacy and safety of rabeprazole in children with endoscopically proven gastroesophageal reflux disease (GERD)." | 5.19 | Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD. ( Haddad, I; Hu, P; Kierkus, J; Leitz, GJ; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2014) |
| " In phase I and III trials of rabeprazole in gastroesophageal reflux disease, we studied serum gastrin levels in infants 1 to 11 months old, and assessed normal ranges and the effect of acid-suppressive drugs." | 5.17 | Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old. ( Hu, P; Sloan, S; Treem, W, 2013) |
| "Evaluate the efficacy and safety of rabeprazole in children, 1 to 11 years old, with endoscopically/histologically proven gastroesophageal reflux disease (GERD)." | 5.17 | Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease. ( Haddad, I; Hu, P; Kierkus, J; Leitz, G; Silber, S; Sloan, S; Tron, E; Ulmer, A, 2013) |
| "Overweight/obesity in GORD patients does not appear to affect the antisecretory efficacy of a single dose of rabeprazole and pantoprazole." | 5.17 | On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? ( Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013) |
| " The aim of this study was to examine the associations between sleep disturbances and refractory gastroesophageal reflux disease (GERD) symptoms in patients receiving once daily proton pump inhibitors (PPI) and the efficacy of twice-daily rabeprazole treatment." | 5.17 | Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment. ( Arakawa, T; Ashida, K; Fujiwara, Y; Habu, Y; Higuchi, K; Kusano, M, 2013) |
| "To seek a promising therapeutic regimen for proton pump inhibitor (PPI)-refractory patients with gastroesophageal reflux disease (GERD) after the standard PPI treatment, we compared the efficacies of rikkunshito (a Japanese traditional medication) combined with rabeprazole (RPZ) and a double dose of RPZ in a prospective randomized multicenter trial in Japanese PPI-refractory GERD patients." | 5.16 | Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan. ( Arakawa, T; Fujimoto, K; Fujiwara, Y; Higuchi, K; Iwakiri, R; Kusano, M; Shimoyama, Y; Tanaka, M; Tominaga, K; Umegaki, E, 2012) |
| "Complete heartburn relief rates were 21% in placebo, 34% in rabeprazole 5 mg and 44% in rabeprazole 10 mg (5 mg vs." | 5.15 | Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. ( Ashida, K; Hongo, M; Kinoshita, Y, 2011) |
| "Administration of 5 mg and 10 mg rabeprazole sufficiently inhibited pathological gastroesophageal acid reflux and relieved heartburn episodes in NERD patients who did not respond to an antacid." | 5.15 | Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study. ( Ashida, K; Hongo, M; Kinoshita, Y, 2011) |
| "The pharmacokinetics of rabeprazole after a single oral dose and once-daily administration for 5 consecutive days was characterized in children 1 to 11 years old with gastroesophageal reflux disease (GERD)." | 5.15 | Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease. ( Doose, DR; Gonzalez, MD; Haddad, I; Leitz, GJ; Mulberg, AE; Rusch, S; Solanki, B; Zannikos, PN, 2011) |
| "Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD and RE) were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks." | 5.15 | Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G ( Chiba, T; Fujiwara, Y; Furuta, T; Hongo, M; Ishihara, S; Kinoshita, Y; Koike, T; Kusano, M; Shimatani, T; Sugimoto, M, 2011) |
| "To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)." | 5.15 | Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011) |
| "To determine if the 4-week efficacy of rabeprazole 20 mg for resolving heartburn and regurgitation symptoms is non-inferior to esomeprazole 40 mg or 20 mg." | 5.14 | Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg. ( Eggleston, A; Holtmann, G; Katelaris, PH; Nandurkar, S; Thorpe, P, 2009) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 5.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "The primary efficacy end point, mean percentage of heartburn-free days, was significantly greater with rabeprazole vs." | 5.14 | Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study. ( Delemos, B; Fass, R; Kao, R; Lu, Y; Nazareno, L; Xiang, J, 2010) |
| " There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor." | 5.14 | Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. ( Gocho, T; Hirohara, S; Iida, T; Misawa, T; Sakamoto, T; Uwagawa, T; Wakiyama, S; Yanaga, K, 2010) |
| "Ten mg dexrabeprazole daily has been shown to be more effective than 20 mg rabeprazole daily against gastroesophageal reflux disease (GERD)." | 5.13 | Ten mg dexrabeprazole daily is as effective as 20 mg rabeprazole daily. ( Jain, S; Kanakia, R, 2008) |
| "To study and document the efficacy and tolerability of rabeprazole and domperidone in the treatment of patients suffering from gastro-oesophageal reflux disease (GERD), an open, prospective, non-comparative study was carried out among 50 adult patients of either sex attending gastroenterology OPD of a leading, tertiary-care teaching hospital in Mumbai with the clinical diagnosis of GERD." | 5.13 | Rabeprazole plus domperidone: the answer for gastro-oesophageal reflux disease. ( Dabholkar, P; Sawant, P; Shahani, S, 2008) |
| "The aim of the study was to evaluate and document the efficacy and tolerability of rabeto plus (FDC of rabeprazole and itopride) in management of functional dyspepsia." | 5.13 | Rabeto plus: a valuable drug for managing functional dyspepsia. ( Basu, M; Dabholkar, P; Ghosh, A; Halder, S; Mandal, A; Mandal, S, 2008) |
| " The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis." | 5.12 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. ( Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M, 2006) |
| "Rabeprazole and pantoprazole are both used for symptomatic treatment of gastro-oesophageal reflux disease (GERD)." | 5.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly." | 5.12 | Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. ( Chiu, HM; Lee, YC; Lin, JT; Wang, HP; Wu, MS, 2007) |
| "To study the acid exposure characteristic of the subtypes of non-erosive gastroesophageal reflux disease (NERD) and discuss the value of rabeprazole in its diagnosis." | 5.12 | [Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole]. ( Fan, YH; Lü, B; Zhan, LX; Zhang, L, 2007) |
| "To evaluate continuous therapy (COT) and on-demand therapy (ODT) with rabeprazole 20 mg for maintenance in uninvestigated gastroesophageal reflux disease (GERD)." | 5.12 | Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. ( Camacho, F; Dinniwell, J; Horbay, GL; Husein-Bhabha, FA; Morgan, DG; O'Mahony, MF; O'Mahony, WF; Roy, J, 2007) |
| " pylori infection on effectiveness of rabeprazole in primary and secondary care patients with gastro-oesophageal reflux disease." | 5.11 | Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? ( Bergmans, P; Boer, WA; Geldof, H; Hazelhoff, B; Smout, AJ; Tytgat, GN; Wit, NJ, 2004) |
| " The aim of this study was to estimate the effects of gastric acid output suppression with rabeprazole on course of angina pectoris and results of the treadmill stress test in patients with CAD." | 5.11 | Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. ( Budzyński, J; Fabisiak, J; Kłopocka, M; Majer, M; Morawski, W; Pulkowski, G; Suppan, K; Swiatkowski, M, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 5.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| "Two hundred and forty-three patients received rabeprazole (20 mg or 10 mg) or omeprazole (20 mg) once daily for up to 5 years, for gastro-oesophageal reflux disease and 51% completed the whole 5 year period." | 5.11 | Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. ( Fiocca, R; Jacobs, A; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2005) |
| "In controlled clinical trials, rabeprazole effectively improves symptoms and heals oesophageal erosions in patients with gastro-oesophageal reflux disease (GORD)." | 5.11 | Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study. ( Archimandritis, AJ; Avgerinos, A; Kouklakis, G; Nikolopoulou, V; Paraskevas, E; Triantafillidis, JK; Tsianos, E, 2005) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "This study aimed to determine whether dysphagia associated with gastroesophageal reflux disease was effectively treated with rabeprazole, a proton pump inhibitor." | 5.11 | Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. ( Danjo, A; Fujimoto, K; Hara, M; Iwakiri, R; Kikkawa, A; Oda, K; Ootani, A; Sakata, H; Shimoda, R; Tsunada, S; Watanabe, K, 2005) |
| "The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease." | 5.11 | Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. ( Johanson, J; Jokubaitis, L; Kahrilas, PJ; Mao, L; Miner, P; Sloan, S, 2005) |
| "To compare the efficacy and safety of two doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive gastro-oesophageal reflux disease over 5 years." | 5.10 | A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. ( Bardhan, KD; Fiocca, R; Humphries, TJ; Miller, N; Morocutti, A; Rindi, G; Thjodleifsson, B, 2003) |
| "Oesophageal pH and heartburn severity were determined in 27 GERD subjects at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way crossover fashion." | 5.10 | Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "Gastric and oesophageal pH were determined in 26 subjects with gastro-oesophageal reflux disease at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way cross-over fashion." | 5.10 | The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. ( Gallo-Torres, H; Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "The research was aimed at evaluating the efficiency of the inhibitor of the Rabeprazole (Pariet) proton pump in the therapy of the gastroesophageal reflux disease (GERD) with extra esophagus manifestations, and the presence of pains in the chest not caused by cardiac diseases." | 5.10 | [Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease]. ( Danilin, MS; Kucheriavyĭ, IuA; Maev, IV, 2003) |
| "This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 34 Helicobacter pylori-negative patients aged 18-60 yr with symptoms of gastroesophageal reflux disease." | 5.10 | Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. ( Chen, Y; Katz, PO; Miner, P; Sostek, M, 2003) |
| "The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health-related quality of life and safety in endoscopically confirmed erosive gastro-oesophageal reflux disease treated with rabeprazole." | 5.10 | Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002) |
| " Rabeprazole is a new proton pump inhibitor that is effective in treating gastro-oesophageal reflux disease (GERD)." | 5.10 | Integrated acidity and rabeprazole pharmacology. ( Barth, JA; Gardner, JD; Hahne, WF; Perdomo, C; Robinson, M; Rodriguez-Stanley, S; Sloan, S, 2002) |
| "Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease." | 5.10 | A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002) |
| "In this randomised, double-blind, multicentre study, conducted at 27 European sites, the efficacy and safety of rabeprazole and omeprazole were compared in patients with erosive or ulcerative gastro-oesophageal reflux disease (GERD)." | 5.09 | Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. ( Beker, JA; Bell, NE; Dekkers, CP; Gabryelewicz, A; Humphries, TJ; Thjodleifsson, B, 1999) |
| "The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease." | 5.09 | Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000) |
| "To evaluate the efficacy and tolerability of rabeprazole 10 mg and 20 mg versus placebo for the prevention of endoscopically demonstrable relapse in patients previously diagnosed with erosive or ulcerative gastro-oesophageal reflux disease (GORD) who had no oesophageal erosions or ulcerations at study entry." | 5.09 | Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. ( Birbara, C; Breiter, J; Hahne, W; Perdomo, C, 2000) |
| "We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD)." | 5.09 | Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group. ( Barth, J; Caos, A; Dayal, Y; Moskovitz, M; Niecestro, R; Perdomo, C, 2000) |
| "Rabeprazole has been shown to be more potent and faster than other proton pump inhibitors in in vitro studies and highly effective in decreasing oesophageal acid exposure in patients with gastro-oesophageal reflux disease (GERD)." | 5.09 | Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. ( Avasthy, N; Ducrottè, P; Fournet, J; Galmiche, JP; Humphries, TJ; Rampal, P; Zerbib, F, 2001) |
| "Rabeprazole, a new proton pump inhibitor, was studied in patients with acid-peptic-related diseases (duodenal ulcer, gastric ulcer, GERD) in three placebo-controlled, double-blind, randomized clinical trials." | 5.08 | Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. ( Bassion, S; Cloud, ML; Enas, N; Humphries, TJ, 1998) |
| " PPIs are the mainstay therapeutic agents for prophylaxis against aspirin gastropathy and for acid-related disorders including gastroesophageal reflux disease." | 4.95 | East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. ( Goh, KL; Zou, D, 2017) |
| " Rabeprazole is a potent and irreversible inhibitor of H(+)/K(+)-ATPase gastric pump, and it is indicated for the treatment of gastroesophageal reflux disease, Zollinger Ellison syndrome, duodenal and gastric ulcers and for the eradication of Helicobacter pylori in combination with antibiotics." | 4.88 | Rabeprazole for the treatment of acid-related disorders. ( Marelli, S; Pace, F, 2012) |
| "Rabeprazole (Aciphex, Alfence, Pariet) is a proton pump inhibitor (PPI) used for the treatment of adults with conditions requiring a reduction of gastric acid secretion such as erosive or ulcerative gastro-oesophageal reflux disease (GORD), non-erosive reflux disease (NERD), duodenal and gastric ulcers, and pathological hypersecretory conditions including Zollinger-Ellison syndrome (ZES)." | 4.85 | Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Baldwin, CM; Keam, SJ, 2009) |
| " Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease." | 4.82 | Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole. ( Horn, J, 2004) |
| " To evaluate the efficacy of the new PPI rabeprazole, 12 controlled clinical trials were conducted worldwide-three for each indication (erosive or ulcerative GERD healing, long-term GERD healing maintenance, duodenal ulcer healing, and gastric ulcer healing)." | 4.81 | Efficacy of rabeprazole once daily for acid-related disorders. ( Bardhan, KD; Barth, J; Lanza, F; Niecestro, R; Perdomo, C, 2001) |
| " When the two newest PPIs, rabeprazole and esomeprazole, are compared with the older drugs in this class (omeprazole, lansoprazole and pantoprazole), the newer PPIs offer several key advantages over older agents, particularly in terms of the management of gastro-oesophageal reflux disease." | 4.81 | New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. ( Robinson, M, 2001) |
| " In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD." | 4.81 | Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001) |
| " Healing rates for rabeprazole were equivalent to omeprazole in all indications, and superior (GORD healing and duodenal ulcer healing) or equivalent (gastric ulcer healing) to the histamine 2-receptor antagonist ranitidine." | 4.80 | The benefit/risk profile of rabeprazole, a new proton-pump inhibitor. ( Barth, J; Johnson, D; Jokubaitis, L; Perdomo, C, 2000) |
| "Gastroesophageal reflux disease (GERD) can be treated using a vonoprazan-first strategy (first-line treatment with vonoprazan), or esomeprazole-first/rabeprazole-first strategies (first-line treatment with proton-pump inhibitors [PPIs], esomeprazole/rabeprazole, followed by a switch to vonoprazan)." | 3.91 | Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD. ( Deguchi, H; Higuchi, K; Igarashi, A; Takeuchi, T; Uda, A; Yokoya, Y, 2019) |
| "We administered rabeprazole 10 mg for 4 weeks to NERD/FD patients, who also answered a modified version of the Frequency Scale for Symptoms of gastroesophageal reflux disease (GERD) (FSSG), which added a pain score to the FSSG." | 3.81 | Pretreatment prediction of symptom response to proton pump inhibitor therapy. ( Asaoka, D; Hojo, M; Matsumoto, K; Miwa, H; Nagahara, A; Osada, T; Sasaki, H; Shimada, Y; Watanabe, S, 2015) |
| "A 59-year-old man was orally administered rabeprazole, a proton pump inhibitor (PPI), for gastroesophageal reflux disease, after which he gradually developed iron-deficiency anemia." | 3.80 | Iron-deficiency anemia caused by a proton pump inhibitor. ( Chonan, A; Hashimoto, R; Matsuda, T, 2014) |
| "Patients with uninvestigated dyspepsia (n = 104; male/female 41/63) were treated with either rabeprazole 10 mg o." | 3.76 | Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia. ( Asaoka, D; Hojo, M; Ishikawa, D; Kawabe, M; Nagahara, A; Oguro, M; Osada, T; Otaka, M; Shimada, Y; Watanabe, S; Yoshizawa, T, 2010) |
| "Consecutive patients presented with GERD symptoms were enrolled to erosive esophagitis (EE) group, non-erosive reflux disease (NERD) group and functional heartburn (FH) group after upper endoscopy, combined MII-pH monitoring and rabeprazole test." | 3.75 | Reflux profile of Chinese gastroesophageal reflux disease patients with combined multichannel intraluminal impedance-pH monitoring. ( Chen, MH; Cheung, TK; Hung, IF; Lin, JK; Peng, S; Wang, AJ; Wong, BC; Wong, NY; Xiao, YL, 2009) |
| "To determine if patients with gastro-oesophageal reflux disease (GERD), who were previously managed on lansoprazole 30 mg twice daily, could be maintained on rabeprazole 20 mg once daily." | 3.74 | Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. ( Coté, GA; Ferreira, MR; Howden, CW; Rozenberg-Ben-Dror, K, 2007) |
| " In a recent study by Pai et al, dexrabeprazole [R(+)-rabeprazole] (10 mg) was found to be more effective than rabeprazole (20 mg) in the treatment of gastroesophageal reflux disease." | 3.74 | Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors? ( Pan, WS; Yan, XF; Zeng, S; Zhou, Q, 2008) |
| "Results of the first week of treatment with rabeprazole in Hp+ and Hp- patients with gastroesophageal reflux disease (GERD) were compared in a large prospective open-label, multicenter, cohort study in general and specialized practices." | 3.73 | Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? ( Bergmans, P; de Boer, W; de Wit, N; Geldof, H; Hazelhoff, B; Smout, A; Tytgat, G, 2006) |
| "From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma." | 3.72 | A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. ( Ashida, S; Fujiki, S; Hosaki, Y; Mitsunobu, F; Mizuno, M; Okada, H; Okamoto, M; Shiratori, Y; Tanizaki, Y; Tsugeno, H, 2003) |
| " However, long-term use of PPIs can cause gut microbiome (GM) disturbances." | 3.11 | Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole. ( Li, Q; Li, Y; Liu, W; Lu, NH; Xiao, Q; Xie, Y; Xu, T; Yang, N; Zhang, H; Zheng, L; Zhou, X; Zuo, K, 2022) |
| " Both drugs were well tolerated, and the adverse event incidence profile was low." | 3.11 | Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease. ( Abdo-Francis, JM; Cabrera-Álvarez, G; Martínez-Torres, H; Remes-Troche, JM, 2022) |
| "Gastro-oesophageal reflux (GOR) is characterised by the regurgitation of gastric contents into the oesophagus." | 3.01 | Pharmacological treatment of gastro-oesophageal reflux in children. ( Afzal, NA; Andrews, E; Beattie, RM; Hayen, A; Liddicoat, I; Tighe, MP, 2023) |
| "Rabeprazole (20 mg) has proved similar Helicobacter pylori eradication rates compared with omeprazole (40 mg) when co-administered with of antibiotics (amoxicillin and clarithromycin) for two weeks." | 2.94 | Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection. ( Amatya, GL; Gurung, SB; Gyawali, P; Kc, SR, 2020) |
| "The extraesophageal manifestations of gastroesophageal reflux disease (GERD) are more difficult to manage than the typical symptoms." | 2.94 | Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial. ( Cho, JH; Kim, N; Lee, DH; Park, YS; Shin, CM; Yoon, H, 2020) |
| "Proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) leads to a clinical decline in the quality of life (QOL)." | 2.90 | Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study. ( Harada, S; Higuchi, K; Hongo, H; Inoue, T; Kimura, T; Kojima, Y; Murano, M; Noguchi, T; Ota, K; Takeuchi, N; Takeuchi, T, 2019) |
| "Gastroesophageal reflux disease (GERD) and functional dyspepsia (FD) often coexist or overlap." | 2.87 | Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. ( Harada, S; Higashino, T; Higuchi, K; Hoshimoto, M; Itabashi, T; Kawaguchi, S; Kojima, K; Kojima, Y; Kuramoto, T; Kusano, M; Ota, K; Sakaguchi, M; Sakamoto, H; Sanomura, M; Takada, K; Takahashi, Y; Takeuchi, T; Tominaga, K, 2018) |
| "A total of 40 patients with GERD treated at the Peking Union Medical College Hospital between September 2004 and July 2006 were randomized to receive DBT and rabeprazole proton pump inhibitor (PPI) or rabeprazole alone." | 2.82 | Short-term and long-term effect of diaphragm biofeedback training in gastroesophageal reflux disease: an open-label, pilot, randomized trial. ( Fang, X; Ke, M; Liu, X; Shang, W; Sun, X; Wang, Z, 2016) |
| "Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment." | 2.82 | Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. ( Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016) |
| "The incidence and severity of gastroesophageal reflux disease (GERD) in Japan tends to increase in elderly women." | 2.79 | Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito. ( Arakawa, T; Fujimoto, K; Furuta, K; Furuta, T; Haruma, K; Higuchi, K; Iwakiri, K; Iwakiri, R; Kato, M; Kinoshita, Y; Kusano, M; Kusunoki, H; Miwa, H; Murakami, K; Nagahara, A; Odaka, T; Sakata, Y; Sakurai, K; Shimoyama, Y; Takahashi, S; Takeda, H; Takeuchi, T; Tominaga, K; Watanabe, S, 2014) |
| "15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily." | 2.77 | Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. ( Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012) |
| "Rabeprazole has a comparable efficacy compared to ranitidine when given on-demand for the treatment of NERD." | 2.77 | A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. ( Aswad, R; El-Samad, S; Haddad, R; Hashash, JG; Jamali, FR; Kobeissy, AA; Ladki, R; Skoury, AM; Soweid, AM, 2012) |
| "Totally 186 patients with GERD were randomly assigned to three groups, i." | 2.77 | [Clinical effects of dalitong granule combined proton pump inhibitors on gastroesophageal reflux disease]. ( Tan, XP; Wang, WZ; Zhang, Q, 2012) |
| " We performed serial endoscopy, checked gastroesophageal reflux disease (GERD) symptoms, adverse events, laboratory values and serum gastrin." | 2.76 | Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. ( Fujimoto, K; Hongo, M, 2011) |
| " Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day." | 2.75 | Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010) |
| "In patients prone to symptoms of supra-esophageal reflux, exercise may trigger gastroesophageal reflux (GER), resulting in such symptoms." | 2.74 | The role of gastroesophageal reflux in exercise-triggered asthma: a randomized controlled trial. ( Fang, JC; Hilden, K; Peterson, KA; Ryujin, DT; Samuelson, WM; Thomas, KL; Young, DC, 2009) |
| "Gastroesophageal reflux disease is thought to be the commonest cause of 'non-cardiac chest pain'." | 2.74 | Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population. ( Azman, W; Goh, KL; Mohd, H; Qua, CS; Wong, CH, 2009) |
| "However, during the second week, GERD-related NCCP had a higher positive PPI test (n = 13, 81%) than non GERD-related NCCP (n = 7, 27%) (P = 0." | 2.74 | Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients. ( Kim, JH; Kim, JJ; Rhee, JC; Rhee, PL; Sinn, DH; Son, HJ, 2009) |
| "Aggressive treatment of GERD in patients with OSAS may be helpful in the overall treatment of this select patient population." | 2.74 | The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease. ( Giddens, CL; Houck, JR; Orr, WC; Robert, JJ; Tawk, MM, 2009) |
| "A new questionnaire for assessing gastroesophageal reflux disease (GERD), the Frequency Scale for Symptoms of GERD, covers the 12 most common symptoms of GERD patients." | 2.73 | Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. ( Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H, 2007) |
| "While gastro-oesophageal reflux disease may be an aggravating factor in patients with globus, it does not appear to be the sole cause of globus symptom." | 2.73 | Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus. ( Kim, JH; Kim, JJ; Kim, S; Rhee, JC; Rhee, PL; Sinn, DH; Son, HJ, 2008) |
| "Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD." | 2.73 | It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients. ( Chiba, T; Hongo, M; Kinoshita, Y; Kusano, M; Shirai, N; Yamaguchi, K, 2008) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 2.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| "In subjects with gastro-oesophageal reflux disease, gastric secretion and integrated gastric acidity from 09." | 2.71 | Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "In subjects with gastro-oesophageal reflux disease treated with a gastric antisecretory agent, the extent to which gastric acidity needs to be reduced to prevent pathological oesophageal acid exposure is not known." | 2.71 | Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "Gastroesophageal reflux disease (GERD) is characterized by heartburn and related symptoms that are distressing to patients and interfere with everyday functioning and well-being." | 2.71 | Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. ( Damiano, A; Johanson, J; Siddique, R; Sloan, S; Xu, X, 2003) |
| " These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms." | 2.71 | Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003) |
| "Ten patients with bruxism and 10 normal subjects were matched for height, weight, age, and sex." | 2.71 | Association between nocturnal bruxism and gastroesophageal reflux. ( Araki, Y; Fujii, A; Katayama, A; Miyawaki, S; Takano-Yamamoto, T; Tanimoto, Y, 2003) |
| "To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers." | 2.71 | Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. ( Junghard, O; Nilsson-Pieschl, C; Nyman, L; Röhss, K; Wilder-Smith, CH, 2003) |
| "Sixteen GERD H." | 2.71 | [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors]. ( Gushchin, AE; Isakov, VA; Morozov, SV; Shipulin, GA; Tsodikova, OM, 2003) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | 2.71 | On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| "Rabeprazole treatment significantly improved subjective indices of sleep quality." | 2.71 | The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. ( Goodrich, S; Orr, WC; Robert, J, 2005) |
| "A cross-over study was made in 27 GERD patients (12 males and 15 females)." | 2.71 | [Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump]. ( Gushchin, AE; Isakov, VA; Morozov, SV; Shipulin, GA; Tereshchenko, SG; Tsodikova, OM, 2005) |
| "Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg." | 2.71 | Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. ( Ang, TL; Chua, TS; Fock, KM; Ng, TM; Tan, YL; Teo, EK, 2005) |
| "Both rabeprazole doses were significantly superior to placebo in preventing relapse of heartburn frequency and improving patient quality of life." | 2.71 | Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. ( Barth, J; Breiter, J; Caos, A; Perdomo, C, 2005) |
| " dosing of rabeprazole." | 2.71 | Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus. ( Hall, M; Higbee, A; Mathur, S; Sampliner, RE; Sharma, P; Wani, S; Weston, AP, 2005) |
| "Patients with moderately severe GERD completed the GSAS and SF-36 at baseline and four weeks following treatment." | 2.70 | Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS). ( Adler, E; Bhattacharyja, A; Damiano, A; Handley, K; Siddique, R, 2002) |
| "Both rabeprazole doses were significantly superior to the placebo with respect to time to the first 24-h heartburn-free interval (2." | 2.70 | Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. ( Filippone, J; Jokubaitis, L; Miner, P; Orr, W; Sloan, S, 2002) |
| "Rabeprazole 20 mg in two different dosing schedules is as effective as omeprazole 20 mg QD with regard to efficacy and tolerability in patients with erosive GERD." | 2.69 | Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. ( Cohen, G; Delchier, JC; Humphries, TJ, 2000) |
| " One of the key distinguishing features of rabeprazole was related to the lesser involvement of polymorphic metabolism in its pharmacokinetic disposition." | 2.58 | Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview. ( Dash, RP; Rais, R; Srinivas, NR, 2018) |
| "Proton-pump inhibitors (PPIs) have been proved as safe and effective ways to treat patients with non-erosive reflux disease (NERD)." | 2.53 | The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. ( Chen, L; Chen, Y; Li, B, 2016) |
| "Rabeprazole 20 mg/d was superior to rabeprazole 10 mg/d in preventing endoscopic relapse of erosive GERD, but that the two dosages were equivalent in symptomatic relief over 1 year." | 2.49 | Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis. ( Lan, Y; Wang, H; Xia, XM; Xu, SM; Zhu, HD, 2013) |
| "Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
| "Gastric acid is pathogenic in many gastrointestinal disorders, such as gastroesophageal reflux disease and peptic ulcer disease." | 2.43 | Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. ( Robinson, M, 2005) |
| " For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status." | 2.43 | Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. ( Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005) |
| "Whether these patients are part of the GERD spectrum or have another diagnosis is not clear." | 2.43 | Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006) |
| "Gastroesophageal reflux disease (GERD) is associated with several symptoms, such as heartburn, belching, and regurgitation, which arise from esophageal exposure to gastric acid." | 2.42 | Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. ( Sloan, S, 2003) |
| "Gastroesophageal reflux disease (GERD) is a wide spread disease characterized by distinct clinical polymorphism manifesting with various symptoms and/or inflammatory changes of a distal portion of the esophagus." | 2.42 | [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease]. ( Balashova, NN; Busarova, GA; Maev, IV, 2003) |
| "Gastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality." | 2.42 | Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. ( Thjodleifsson, B, 2004) |
| "Rabeprazole is a second generation PPI with rapid onset of action that quickly relieves symptoms of GERD." | 2.42 | Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease. ( Goh, KL; Lim, PW, 2004) |
| "Lansoprazole was superior to famotidine with regard to both efficacy and cost-effectiveness and therefore is the preferred therapeutic agent for the maintenance treatment of GERD." | 2.42 | [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist]. ( Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T, 2004) |
| "Initial therapy of GERD should be started with a full dose of PPI." | 2.42 | [PPI: new strategies for GERD]. ( Hoshino, E; Ishiyama, A; Tsuchida, T, 2004) |
| "Rabeprazole is a newer generation proton pump inhibitor that suppresses the gastric proton pump and acid secretion more rapidly than does omeprazole, lansoprazole or pantoprazole." | 2.42 | Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. ( Miner, P, 2004) |
| "Gastroesophageal reflux disease is a complex, multifaceted disorder affecting a large proportion of the US population." | 2.41 | The pharmacology and clinical relevance of proton pump inhibitors. ( Frissora, C; Katz, PO, 2002) |
| "Rabeprazole is an inhibitor of the gastric proton pump." | 2.40 | Rabeprazole: a review of its use in acid-related gastrointestinal disorders. ( Langtry, HD; Markham, A, 1999) |
| "There is no curative treatment for gastroesophageal reflux disease." | 1.91 | The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment. ( Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A, 2023) |
| "However, effect of BILs in refractory GERD (RGERD) has not been well investigated." | 1.43 | Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors. ( Jiang, L; Lin, L; Wang, M; Wang, Y; Ye, B, 2016) |
| "Symptom eradication in patients with Barrett's esophagus (BE) does not guarantee control of acid or duodenogastroesophageal reflux (DGER)." | 1.42 | Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus. ( Bhat, YM; Falk, GW; Maqbool, S; Richter, JE; Vaezi, MF; Yachimski, P, 2015) |
| "To clarify the pathogenesis of gastroesophageal reflux disease symptoms in non-erosive reflux disease (NERD) patients." | 1.42 | Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients. ( Ara, N; Asano, N; Hatta, W; Iijima, K; Kikuchi, H; Koike, T; Nakagawa, K; Saito, M; Shimosegawa, T; Uno, K, 2015) |
| "It is suggested that nonalcoholic fatty liver disease (NAFLD), including nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), can be associated with insomnia and gastro-esophageal reflux disease (GERD)." | 1.40 | The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. ( Chayama, K; Eguchi, Y; Fujii, H; Fujimoto, K; Hyogo, H; Imajo, K; Itoh, Y; Kanemasa, K; Nakajima, A; Ono, M; Saibara, T; Sumida, Y; Taketani, H; Tanaka, S; Yoneda, M; Yoshikawa, T, 2014) |
| "Treatment with rabeprazole resulted in a decrease from 18." | 1.38 | Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors. ( Hongo, M; Kusano, M; Miwa, H, 2012) |
| "A total of 5,279 GERD patients with Frequency Scale for the Symptoms of GERD (FSSG) scores ≥ 8 points at baseline were analyzed." | 1.38 | Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. ( Hongo, M; Kusano, M; Miwa, H, 2012) |
| " Food and Drug Administration advised that long-term use of PPI can induce hypomagnesemia." | 1.38 | Hypomagnesemia associated with a proton pump inhibitor. ( Doyama, H; Hayashi, T; Ito, R; Kanaya, H; Kim, F; Kito, Y; Matsuyama, J; Nakanishi, H; Okada, T; Takeda, Y; Takemura, K; Tsuji, K; Tsuji, S; Waseda, Y; Yamada, S, 2012) |
| "Patients with GERD and a control group of healthy asymptomatic volunteers were recruited." | 1.37 | Non-erosive reflux disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD): from hypersensitive to hyposensitive esophagus. ( Goh, KL; Hartono, JL; Qua, CS, 2011) |
| "Despite consensus recommendations, eosinophilic esophagitis (EoE) is commonly diagnosed upon esophageal eosinophilic infiltration (EEI; based on ≥ 15 eosinophils per high power field; eo/HPF)." | 1.37 | Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. ( Dueñas, C; Fernandez-Bermejo, M; Fernandez-Gonzalez, N; Ferrando-Lamana, L; Gonzalez-Nuñez, MA; Hernandez-Alonso, M; Mateos, JM; Molina-Infante, J; Quintana, EM; Ripoll, C, 2011) |
| "Rabeprazole treatment significantly decreased both the FSSG and the PSQI score." | 1.36 | Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole. ( Arakawa, T; Fujiwara, Y; Hayakawa, T; Kaji, M; Kohata, Y; Machida, H; Nebiki, H; Sasaki, E; Tanigawa, T; Tominaga, K; Watanabe, K; Watanabe, T; Yamasaki, T, 2010) |
| "Risk factors were hiatus hernia; severe past erosive GERD (grade C or D); H." | 1.36 | Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan. ( Fujimoto, K; Hongo, M, 2010) |
| "Rabeprazole is a proton pump inhibitor (PPI) presenting a very advantageous pharmacodynamic and pharmacokinetic profile over older PPIs." | 1.35 | Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. ( Marelli, S; Pace, F; Pallotta, S, 2008) |
| "Group 1 comprised 47 patients with GERD and group 2 49 patients with gastric and duodenal UD." | 1.35 | [Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer]. ( Andreev, NG; Beliantseva, EV; Golubev, NN; Maev, IV; Odintsova, AN; Samsonov, AA, 2009) |
| "Treatment with Rabeprazole helps efficiently jugulate reflux disease symptoms and accurately improve quality of life index." | 1.35 | [The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy]. ( Golubev, NN; Iablunovskaia, GI; Maev, IV; Odintsova, AN; Samsonov, AA, 2009) |
| "Gastroesophageal reflux disease (GERD) is a well-recognized cause of impaired sleep in patients with frequent GERD symptoms, as well as those with sleep apnea." | 1.35 | Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy. ( Alattar, M; Davis, PH; Galanko, JA; Madanick, RD; Morgan, DR; Shaheen, NJ; Spacek, MB; Vaughn, BV, 2008) |
| "A subset of patients with gastro-oesophageal reflux disease (GERD) does not achieve complete symptom resolution with proton pump inhibitor (PPI) therapy." | 1.35 | The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. ( Adlis, SA; Chey, WD; Nojkov, B; Rai, J; Rubenstein, JH; Saad, R; Shaw, MJ; Weinman, B, 2008) |
| "The prevalence of pathologic 24-hour esophageal reflux in both studies was significantly higher when measured as time pH < 4 than when measured as integrated acidity." | 1.35 | Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors. ( Gardner, JD; Gerson, LB; Miner, PB; Robinson, M; Sahbaie, P; Sloan, S; Triadafilopoulos, G; Young, W, 2008) |
| "Using GERD as an example, the authors were able to determine differences in patient satisfaction between proton pump inhibitors (PPIs), H(2) antagonists, and antacids, and even within the PPI category, down to individual products." | 1.34 | Comparative drug effects: the case of GERD therapies. ( Wertheimer, AI; Wilson, JM, 2007) |
| "Rabeprazole 10 mg/day was administered for 4 weeks to 180 patients who kept symptom diaries." | 1.34 | Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. ( Chiba, T; Fujiwara, Y; Furuta, T; Habu, Y; Hongo, M; Ito, M; Kinoshita, Y; Koike, T; Miwa, H; Nagahara, A; Sasaki, M; Wada, T, 2007) |
| "The article covers the modem concept of gastroesophageal reflux disease (GERD) pharmacogenomics." | 1.33 | [Pharmacogenomical aspects of gastroesophageal reflux disease]. ( Isaev, VA, 2005) |
| " Long-term dosing schedule (high dose or step-down dose) was based on current market data." | 1.33 | Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. ( Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005) |
| "The Gastroesophageal Reflux Disease (GERD) Treatment Satisfaction Questionnaire (GTSQ) was developed to assess satisfaction with GERD medication." | 1.33 | Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire. ( Dodd, SL; Flood, E; Howell, J; Shikiar, R; Siddique, R, 2005) |
| "Rabeprazole was administered on days 2-4 of the study (20 mg orally twice a day)." | 1.33 | Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy. ( Hirano, I; Kahrilas, PJ; Pandolfino, JE; Zhang, Q, 2005) |
| "The scale of GERD-HRQL decreased significantly in RE patients than in NERD patients." | 1.33 | [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease]. ( Hou, XH; Ke, MY; Liu, XH; Luo, JY; Song, ZQ; Sun, J; Yuan, YZ; Zha, H; Zhu, YL, 2005) |
| "The subjects were 88 patients with gastroesophageal reflux disease (GERD), who had changes in the oral cavity typical of this disease." | 1.33 | [Oral cavity manifestations of gastroesophageal reflux disease]. ( Barer, GM; Burkov, SG; Busarova, GA; Gurenev, GL; Maev, IV; Polikanova, EN; Pustovoĭt, EV, 2005) |
| " Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy." | 1.33 | Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. ( Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006) |
| "Rabeprazole is a PPI whose metabolism shows fewer interactions compared to other PPIs." | 1.33 | Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. ( Giannini, EG; Savarino, V; Testa, R, 2006) |
| "Gastroesophageal reflux disease (GERD), is a common disorder." | 1.32 | Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. ( Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I, 2004) |
| "Thirty-two patients with long-segment Barrett esophagus who were asymptomatic with PPIs." | 1.32 | Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. ( Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS, 2004) |
| "Rabeprazole subjects had lower GERD-related costs, less escalation, and lower DACON (measured as number of tablets consumed per day), compared to lansoprazole and omeprazole subjects." | 1.31 | Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. ( Dodd, S; Durkin, M; Hall, J; Sloan, S, 2002) |
| "Patients with erosive gastroesophageal reflux disease participating in an open-label, 8-week study completed the SF-36 Health Survey before and after treatment with rabeprazole." | 1.31 | Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease. ( Bhattacharjya, A; Damiano, AM; Johanson, JF; Jokubaitis, L; Murthy, A; Siddique, R, 2002) |
| "Rabeprazole has also been shown to have a more consistent suppression of acid, including at night." | 1.31 | Optimizing acid-suppression therapy. ( Barnett, JL; Robinson, M, 2001) |
| "Rabeprazole has a favourable profile with rapid action and good safety." | 1.31 | [Pharma-clinics medication of the month. Rabeprazole (Pariet)]. ( Louis, E, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (2.86) | 18.2507 |
| 2000's | 154 (62.86) | 29.6817 |
| 2010's | 72 (29.39) | 24.3611 |
| 2020's | 12 (4.90) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Oshima, T | 2 |
| Igarashi, A | 2 |
| Nakano, H | 1 |
| Deguchi, H | 2 |
| Fujimori, I | 1 |
| Fernandez, J | 1 |
| Liu, W | 1 |
| Xie, Y | 1 |
| Li, Y | 1 |
| Zheng, L | 1 |
| Xiao, Q | 1 |
| Zhou, X | 1 |
| Li, Q | 1 |
| Yang, N | 1 |
| Zuo, K | 1 |
| Xu, T | 1 |
| Lu, NH | 1 |
| Zhang, H | 1 |
| Barberio, B | 1 |
| Visaggi, P | 1 |
| Savarino, E | 3 |
| de Bortoli, N | 1 |
| Black, CJ | 1 |
| Ford, AC | 1 |
| Abdo-Francis, JM | 2 |
| Cabrera-Álvarez, G | 1 |
| Martínez-Torres, H | 1 |
| Remes-Troche, JM | 1 |
| Kasap, E | 1 |
| Buran, T | 1 |
| Toraman Avcu, A | 1 |
| Solmaz Hasdemir, P | 1 |
| Balcan, E | 1 |
| Aktan, Ç | 1 |
| Korkmaz, M | 1 |
| Tighe, MP | 1 |
| Andrews, E | 1 |
| Liddicoat, I | 1 |
| Afzal, NA | 1 |
| Hayen, A | 1 |
| Beattie, RM | 1 |
| López-Suárez, CM | 1 |
| Yokoya, Y | 1 |
| Uda, A | 1 |
| Takeuchi, T | 5 |
| Higuchi, K | 7 |
| Gurung, SB | 1 |
| Kc, SR | 1 |
| Gyawali, P | 1 |
| Amatya, GL | 1 |
| Cho, JH | 1 |
| Shin, CM | 2 |
| Yoon, H | 1 |
| Park, YS | 1 |
| Kim, N | 2 |
| Lee, DH | 2 |
| Manabe, N | 3 |
| Yamamoto, T | 1 |
| Matsusaki, M | 1 |
| Akashi, M | 1 |
| Haruma, K | 2 |
| Takahashi, Y | 1 |
| Kawaguchi, S | 2 |
| Ota, K | 2 |
| Harada, S | 3 |
| Kojima, Y | 3 |
| Sakamoto, H | 1 |
| Kuramoto, T | 1 |
| Kojima, K | 1 |
| Sanomura, M | 2 |
| Hoshimoto, M | 2 |
| Higashino, T | 1 |
| Itabashi, T | 2 |
| Takada, K | 1 |
| Sakaguchi, M | 2 |
| Tominaga, K | 4 |
| Kusano, M | 11 |
| Kinoshita, Y | 9 |
| Kato, M | 2 |
| Fujishiro, M | 1 |
| Masuyama, H | 1 |
| Nakata, R | 1 |
| Abe, H | 1 |
| Kumagai, S | 1 |
| Fukushima, Y | 1 |
| Okubo, Y | 1 |
| Hojo, S | 1 |
| Lu, B | 2 |
| Zhang, L | 2 |
| Wang, J | 2 |
| Wang, B | 1 |
| Zou, X | 1 |
| Fei, G | 1 |
| Chen, D | 1 |
| Wang, X | 1 |
| Wu, B | 1 |
| Zou, D | 2 |
| Hongo, H | 1 |
| Kimura, T | 1 |
| Takeuchi, N | 2 |
| Noguchi, T | 1 |
| Inoue, T | 1 |
| Murano, M | 1 |
| Takeda, N | 1 |
| Takemura, M | 1 |
| Kanemitsu, Y | 1 |
| Hijikata, H | 1 |
| Fukumitsu, K | 1 |
| Asano, T | 1 |
| Yamaba, Y | 1 |
| Suzuki, M | 1 |
| Kubota, E | 1 |
| Kamiya, T | 1 |
| Ueda, T | 1 |
| Niimi, A | 1 |
| Huo, X | 1 |
| Souza, RF | 1 |
| Duman, M | 1 |
| Polat, E | 1 |
| Ozer, M | 1 |
| Demirci, Y | 1 |
| Yasar, NF | 1 |
| Akyuz, C | 1 |
| Uzun, O | 1 |
| Peker, KD | 1 |
| Genc, E | 1 |
| Yol, S | 1 |
| Yamashita, H | 1 |
| Ashida, K | 4 |
| Fukuchi, T | 1 |
| Nagatani, Y | 1 |
| Koga, H | 1 |
| Senda, K | 1 |
| Eguchi, T | 1 |
| Ubukata, S | 1 |
| Ueda, A | 1 |
| Tanaka, T | 3 |
| Ohashi, R | 1 |
| Ito, D | 1 |
| Treem, W | 3 |
| Hu, P | 4 |
| Sloan, S | 17 |
| Haddad, I | 3 |
| Kierkus, J | 3 |
| Tron, E | 2 |
| Ulmer, A | 2 |
| Silber, S | 2 |
| Leitz, G | 1 |
| Bruley des Varannes, S | 1 |
| Coudsy, B | 2 |
| Waechter, S | 1 |
| Delemos, B | 5 |
| Xiang, J | 4 |
| Lococo, J | 3 |
| Ducrotté, P | 2 |
| Taketani, H | 1 |
| Sumida, Y | 1 |
| Tanaka, S | 1 |
| Imajo, K | 1 |
| Yoneda, M | 1 |
| Hyogo, H | 1 |
| Ono, M | 1 |
| Fujii, H | 1 |
| Eguchi, Y | 1 |
| Kanemasa, K | 1 |
| Chayama, K | 1 |
| Itoh, Y | 1 |
| Yoshikawa, T | 1 |
| Saibara, T | 1 |
| Fujimoto, K | 7 |
| Nakajima, A | 1 |
| Zhu, HD | 1 |
| Wang, H | 1 |
| Xia, XM | 1 |
| Xu, SM | 1 |
| Lan, Y | 1 |
| Fujiwara, Y | 6 |
| Habu, Y | 4 |
| Arakawa, T | 4 |
| Hussain, S | 1 |
| Hoffman, D | 1 |
| Lekich, R | 1 |
| Leitz, GJ | 2 |
| Sakata, Y | 1 |
| Takeda, H | 3 |
| Shimoyama, Y | 3 |
| Iwakiri, R | 4 |
| Furuta, K | 2 |
| Sakurai, K | 1 |
| Odaka, T | 1 |
| Kusunoki, H | 1 |
| Nagahara, A | 4 |
| Iwakiri, K | 2 |
| Furuta, T | 9 |
| Murakami, K | 1 |
| Miwa, H | 6 |
| Takahashi, S | 1 |
| Watanabe, S | 3 |
| McLeay, SC | 1 |
| Green, B | 1 |
| Thyssen, A | 1 |
| Mannaert, E | 1 |
| Kimko, H | 1 |
| Hashimoto, R | 1 |
| Matsuda, T | 1 |
| Chonan, A | 1 |
| Chung, KH | 1 |
| Jin, E | 1 |
| Cho, Y | 1 |
| Seo, JY | 1 |
| Jeong, SH | 1 |
| Kim, JW | 2 |
| Hwang, JH | 1 |
| Oota, K | 1 |
| Edogawa, S | 1 |
| Hayashi, K | 1 |
| Hongoh, Y | 1 |
| Kitae, H | 1 |
| Asaoka, D | 2 |
| Shimada, Y | 2 |
| Sasaki, H | 1 |
| Matsumoto, K | 1 |
| Osada, T | 2 |
| Hojo, M | 2 |
| Suzuki, T | 3 |
| Matsushima, M | 1 |
| Masui, A | 1 |
| Tsuda, S | 1 |
| Imai, J | 1 |
| Nakamura, J | 1 |
| Tsukune, Y | 1 |
| Uchida, T | 1 |
| Yuhara, H | 1 |
| Igarashi, M | 1 |
| Koike, J | 1 |
| Mine, T | 1 |
| Yachimski, P | 1 |
| Maqbool, S | 1 |
| Bhat, YM | 1 |
| Richter, JE | 1 |
| Falk, GW | 1 |
| Vaezi, MF | 1 |
| Sun, X | 1 |
| Shang, W | 1 |
| Wang, Z | 1 |
| Liu, X | 1 |
| Fang, X | 1 |
| Ke, M | 1 |
| Nakagawa, K | 1 |
| Koike, T | 3 |
| Iijima, K | 1 |
| Saito, M | 1 |
| Kikuchi, H | 1 |
| Hatta, W | 1 |
| Ara, N | 1 |
| Uno, K | 1 |
| Asano, N | 1 |
| Shimosegawa, T | 1 |
| Jiang, L | 1 |
| Ye, B | 1 |
| Lin, L | 1 |
| Wang, Y | 1 |
| Wang, M | 1 |
| Chen, L | 1 |
| Chen, Y | 2 |
| Li, B | 1 |
| Çelebi, A | 1 |
| Aydın, D | 1 |
| Kocaman, O | 1 |
| Konduk, BT | 1 |
| Şentürk, Ö | 1 |
| Hülagü, S | 1 |
| Goh, KL | 5 |
| Dash, RP | 1 |
| Rais, R | 1 |
| Srinivas, NR | 1 |
| Garrean, CP | 1 |
| Zhang, Q | 3 |
| Gonsalves, N | 1 |
| Hirano, I | 3 |
| Xirouchakis, E | 1 |
| Kamberoglou, D | 1 |
| Kalos, D | 1 |
| Zambeli, E | 1 |
| Doulgeroglou, V | 1 |
| Tzias, V | 1 |
| Oridate, N | 1 |
| Mesuda, Y | 1 |
| Nishizawa, N | 1 |
| Furuta, Y | 1 |
| Asaka, M | 1 |
| Fukuda, S | 1 |
| Kanakia, R | 1 |
| Jain, S | 1 |
| Peterson, KA | 1 |
| Samuelson, WM | 1 |
| Ryujin, DT | 1 |
| Young, DC | 1 |
| Thomas, KL | 1 |
| Hilden, K | 1 |
| Fang, JC | 1 |
| Shahani, S | 1 |
| Sawant, P | 1 |
| Dabholkar, P | 2 |
| Mohd, H | 1 |
| Qua, CS | 2 |
| Wong, CH | 1 |
| Azman, W | 1 |
| Pallotta, S | 1 |
| Pace, F | 4 |
| Marelli, S | 2 |
| Eggleston, A | 1 |
| Katelaris, PH | 1 |
| Nandurkar, S | 1 |
| Thorpe, P | 1 |
| Holtmann, G | 2 |
| Pellicano, R | 1 |
| Ghosh, A | 1 |
| Halder, S | 1 |
| Mandal, S | 1 |
| Mandal, A | 1 |
| Basu, M | 1 |
| Kim, JH | 2 |
| Sinn, DH | 2 |
| Son, HJ | 2 |
| Kim, JJ | 2 |
| Rhee, JC | 2 |
| Rhee, PL | 2 |
| Baldwin, CM | 1 |
| Keam, SJ | 1 |
| Jain, SC | 1 |
| Xiao, YL | 3 |
| Lin, JK | 3 |
| Cheung, TK | 1 |
| Wong, NY | 1 |
| Hung, IF | 1 |
| Wong, BC | 2 |
| Peng, S | 3 |
| Wang, AJ | 3 |
| Chen, MH | 3 |
| Wu, JC | 1 |
| Maev, IV | 6 |
| Samsonov, AA | 2 |
| Beliantseva, EV | 1 |
| Golubev, NN | 2 |
| Odintsova, AN | 2 |
| Andreev, NG | 1 |
| Sugimoto, M | 7 |
| Nishino, M | 4 |
| Kodaira, C | 3 |
| Yamade, M | 3 |
| Ikuma, M | 3 |
| Sugimura, H | 1 |
| Hishida, A | 2 |
| Iablunovskaia, GI | 1 |
| Orr, WC | 2 |
| Robert, JJ | 1 |
| Houck, JR | 1 |
| Giddens, CL | 1 |
| Tawk, MM | 1 |
| Kohata, Y | 1 |
| Kaji, M | 1 |
| Nebiki, H | 1 |
| Yamasaki, T | 1 |
| Sasaki, E | 1 |
| Hayakawa, T | 1 |
| Machida, H | 1 |
| Tanigawa, T | 1 |
| Watanabe, K | 2 |
| Watanabe, T | 1 |
| Miner, P | 5 |
| Ieni, J | 1 |
| Fass, R | 2 |
| Nazareno, L | 1 |
| Kao, R | 2 |
| Lu, Y | 1 |
| Yang, XL | 1 |
| Liu, XH | 2 |
| Ke, MY | 2 |
| Song, ZQ | 2 |
| Yuan, YZ | 2 |
| Luo, JY | 2 |
| Hou, XH | 2 |
| Hartono, JL | 1 |
| Oguro, M | 1 |
| Ishikawa, D | 1 |
| Kawabe, M | 1 |
| Yoshizawa, T | 1 |
| Otaka, M | 1 |
| Sano, H | 1 |
| Tanaka, Y | 1 |
| Kawami, N | 1 |
| Umezawa, M | 1 |
| Futagami, S | 1 |
| Hoshihara, Y | 1 |
| Nomura, T | 1 |
| Miyashita, M | 1 |
| Sakamoto, C | 1 |
| Hongo, M | 11 |
| Uwagawa, T | 1 |
| Misawa, T | 1 |
| Iida, T | 1 |
| Sakamoto, T | 1 |
| Gocho, T | 1 |
| Wakiyama, S | 1 |
| Hirohara, S | 1 |
| Yanaga, K | 1 |
| Tao, J | 1 |
| Hu, PJ | 1 |
| Molina-Infante, J | 1 |
| Ferrando-Lamana, L | 1 |
| Ripoll, C | 1 |
| Hernandez-Alonso, M | 1 |
| Mateos, JM | 1 |
| Fernandez-Bermejo, M | 1 |
| Dueñas, C | 1 |
| Fernandez-Gonzalez, N | 1 |
| Quintana, EM | 1 |
| Gonzalez-Nuñez, MA | 1 |
| Sone, M | 2 |
| Kato, T | 1 |
| Suzuki, Y | 1 |
| Arao, H | 1 |
| Sugiyama, K | 1 |
| Ishida, K | 1 |
| Izawa, K | 1 |
| Takasu, A | 1 |
| Nakashima, T | 2 |
| Miyashita, T | 2 |
| Shah, FA | 2 |
| Marti, GP | 2 |
| Bonde, P | 1 |
| Gibson, MK | 1 |
| Ohta, T | 2 |
| Montgomery, EA | 1 |
| Duncan, M | 1 |
| Harmon, JW | 2 |
| Stanghellini, V | 1 |
| Frisoni, C | 1 |
| Zannikos, PN | 1 |
| Doose, DR | 1 |
| Rusch, S | 1 |
| Gonzalez, MD | 1 |
| Solanki, B | 1 |
| Mulberg, AE | 1 |
| Kahrilas, PJ | 3 |
| Hughes, N | 1 |
| Howden, CW | 2 |
| Uotani, T | 2 |
| Umemura, K | 1 |
| Zentilin, P | 1 |
| Dulbecco, P | 2 |
| Malesci, A | 1 |
| Savarino, V | 3 |
| Kira, F | 1 |
| Suyama, Y | 1 |
| Nishimura, S | 1 |
| Ogura, K | 1 |
| Liang, MJ | 1 |
| Jiang, AY | 1 |
| Chen, J | 1 |
| Wen, WP | 1 |
| Shimatani, T | 5 |
| Ishihara, S | 1 |
| Chiba, T | 5 |
| Sun, Y | 1 |
| Casalini, S | 2 |
| Li, H | 1 |
| Pelosini, I | 1 |
| Scarpignato, C | 1 |
| Tanaka, M | 1 |
| Umegaki, E | 1 |
| Adachi, K | 1 |
| Ito, M | 3 |
| Kurosawa, S | 2 |
| Mannen, K | 1 |
| Lee, KJ | 1 |
| Kim, JI | 1 |
| Park, JS | 1 |
| Moon, BS | 1 |
| Kim, SG | 1 |
| Chun, JH | 1 |
| Jung, HY | 1 |
| Choi, CH | 1 |
| Chun, SW | 1 |
| Song, GA | 1 |
| Choi, MG | 1 |
| Chun, HJ | 1 |
| Kobeissy, AA | 1 |
| Hashash, JG | 1 |
| Jamali, FR | 1 |
| Skoury, AM | 1 |
| Haddad, R | 1 |
| El-Samad, S | 1 |
| Ladki, R | 1 |
| Aswad, R | 1 |
| Soweid, AM | 1 |
| Aktaş, B | 1 |
| Başar, Ö | 1 |
| Altinbaş, A | 1 |
| Ekiz, F | 1 |
| Yüksel, O | 1 |
| Tan, XP | 1 |
| Wang, WZ | 1 |
| Matsuyama, J | 1 |
| Tsuji, K | 1 |
| Doyama, H | 1 |
| Kim, F | 1 |
| Takeda, Y | 1 |
| Kito, Y | 1 |
| Ito, R | 1 |
| Nakanishi, H | 1 |
| Hayashi, T | 1 |
| Waseda, Y | 1 |
| Tsuji, S | 1 |
| Takemura, K | 1 |
| Yamada, S | 1 |
| Okada, T | 1 |
| Kanaya, H | 1 |
| Hata, S | 1 |
| Arai, M | 1 |
| Maruoka, D | 1 |
| Matsumura, T | 1 |
| Nakagawa, T | 1 |
| Katsuno, T | 1 |
| Imazeki, F | 1 |
| Yokosuka, O | 1 |
| Takubo, K | 1 |
| Tanaka, J | 2 |
| Aida, J | 1 |
| Joh, T | 1 |
| Wada, T | 2 |
| Watanabe, Y | 1 |
| Komatsu-Tanaka, M | 1 |
| Inamori, M | 1 |
| Akiyama, J | 1 |
| Ando, T | 1 |
| Kinjo, F | 1 |
| Deguchi, R | 1 |
| Matsui, D | 1 |
| Okamoto, K | 1 |
| Makino, I | 1 |
| Hayashi, H | 2 |
| Oyama, K | 1 |
| Nakagawara, H | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Murakami, M | 1 |
| Ninomiya, I | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Damiano, A | 2 |
| Handley, K | 1 |
| Adler, E | 1 |
| Siddique, R | 4 |
| Bhattacharyja, A | 1 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Hall, J | 1 |
| Dodd, S | 1 |
| Durkin, M | 1 |
| Johnson, M | 1 |
| Guilford, S | 1 |
| Libretto, SE | 1 |
| Vasil'ev, IuV | 2 |
| Noskova, KK | 1 |
| Zelenikin, SA | 1 |
| Katz, PO | 3 |
| Frissora, C | 1 |
| Johanson, JF | 1 |
| Damiano, AM | 1 |
| Jokubaitis, L | 5 |
| Murthy, A | 2 |
| Bhattacharjya, A | 1 |
| Thjodleifsson, B | 4 |
| Rindi, G | 2 |
| Fiocca, R | 2 |
| Humphries, TJ | 7 |
| Morocutti, A | 4 |
| Miller, N | 3 |
| Bardhan, KD | 2 |
| Gardner, JD | 8 |
| Miner, PB | 8 |
| Robinson, M | 13 |
| Xu, X | 1 |
| Johanson, J | 2 |
| Tsugeno, H | 1 |
| Mizuno, M | 1 |
| Fujiki, S | 1 |
| Okada, H | 1 |
| Okamoto, M | 1 |
| Hosaki, Y | 1 |
| Ashida, S | 1 |
| Mitsunobu, F | 1 |
| Tanizaki, Y | 1 |
| Shiratori, Y | 1 |
| Laheij, RJ | 1 |
| Van Rossum, LG | 1 |
| Jansen, JB | 1 |
| Verheugt, FW | 1 |
| Hellström, PM | 1 |
| Vitols, S | 1 |
| Balashova, NN | 1 |
| Busarova, GA | 2 |
| Pehlivanov, ND | 1 |
| Olyaee, M | 1 |
| Sarosiek, I | 1 |
| McCallum, RW | 1 |
| Gallo-Torres, H | 1 |
| Kucheriavyĭ, IuA | 1 |
| Danilin, MS | 1 |
| Starostin, BD | 1 |
| Starostina, GA | 1 |
| Miyawaki, S | 1 |
| Tanimoto, Y | 1 |
| Araki, Y | 1 |
| Katayama, A | 1 |
| Fujii, A | 1 |
| Takano-Yamamoto, T | 1 |
| Ivashkin, VT | 1 |
| Trukhmanov, AS | 1 |
| Sostek, M | 1 |
| Wilder-Smith, CH | 1 |
| Röhss, K | 2 |
| Nilsson-Pieschl, C | 1 |
| Junghard, O | 1 |
| Nyman, L | 1 |
| Kivioja, A | 1 |
| Linnosmaa, I | 1 |
| Vehviläinen, A | 1 |
| Vohlonen, I | 1 |
| Morozov, SV | 2 |
| Tsodikova, OM | 2 |
| Isakov, VA | 2 |
| Gushchin, AE | 2 |
| Shipulin, GA | 2 |
| Alfonzo, CA | 1 |
| Bobo, WV | 1 |
| Almond, MD | 1 |
| Sarela, AI | 1 |
| Hick, DG | 1 |
| Verbeke, CS | 1 |
| Casey, JF | 1 |
| Guillou, PJ | 1 |
| Clark, GW | 1 |
| Bytzer, P | 3 |
| Blum, A | 1 |
| De Herdt, D | 1 |
| Dubois, D | 1 |
| Wit, NJ | 1 |
| Boer, WA | 1 |
| Geldof, H | 2 |
| Hazelhoff, B | 2 |
| Bergmans, P | 2 |
| Tytgat, GN | 1 |
| Smout, AJ | 1 |
| Ponce, J | 1 |
| Argüello, L | 1 |
| Bastida, G | 1 |
| Ponce, M | 1 |
| Ortiz, V | 1 |
| Garrigues, V | 1 |
| Lim, PW | 2 |
| Swiatkowski, M | 1 |
| Budzyński, J | 1 |
| Kłopocka, M | 1 |
| Pulkowski, G | 1 |
| Suppan, K | 1 |
| Fabisiak, J | 1 |
| Morawski, W | 1 |
| Majer, M | 1 |
| Yoshino, T | 1 |
| Shio, S | 1 |
| Hayakumo, T | 1 |
| Kawai, K | 1 |
| Hoshino, E | 1 |
| Ishiyama, A | 1 |
| Tsuchida, T | 1 |
| Lind, T | 1 |
| Wilder-Smith, C | 1 |
| Hong, SP | 1 |
| Park, PW | 1 |
| Hwang, SG | 1 |
| Ko, KH | 1 |
| Kwak, SY | 1 |
| Kim, SH | 1 |
| Kwon, KS | 1 |
| Shin, YW | 1 |
| Ryu, JK | 1 |
| Ryu, KH | 1 |
| Park, SJ | 1 |
| Won, WH | 1 |
| Yoo, HM | 1 |
| Bae, HM | 1 |
| Park, MJ | 1 |
| Woo, YK | 1 |
| Kim, KC | 1 |
| Kim, KH | 1 |
| Na, SH | 1 |
| Khavkin, AI | 1 |
| Zhikhareva, NS | 1 |
| Rachkova, NS | 1 |
| Babaian, ML | 1 |
| Volynets, GV | 1 |
| Khanakaeva, ZK | 1 |
| Steward, DL | 1 |
| Wilson, KM | 1 |
| Kelly, DH | 1 |
| Patil, MS | 1 |
| Schwartzbauer, HR | 1 |
| Long, JD | 1 |
| Welge, JA | 1 |
| Horn, J | 1 |
| Minushkin, ON | 2 |
| Maslovskiĭ, LV | 2 |
| Anikina, NIu | 2 |
| Livzan, MA | 1 |
| Kononov, AV | 1 |
| Goodrich, S | 1 |
| Robert, J | 1 |
| Tereshchenko, SG | 1 |
| Jacobs, A | 1 |
| Archimandritis, AJ | 1 |
| Nikolopoulou, V | 1 |
| Kouklakis, G | 1 |
| Paraskevas, E | 1 |
| Avgerinos, A | 1 |
| Tsianos, E | 1 |
| Triantafillidis, JK | 1 |
| Oh, DS | 1 |
| Ohning, GV | 1 |
| Pisegna, JR | 1 |
| Fock, KM | 1 |
| Teo, EK | 1 |
| Ang, TL | 1 |
| Chua, TS | 1 |
| Ng, TM | 1 |
| Tan, YL | 1 |
| Shuleshova, AG | 1 |
| Shirai, N | 3 |
| Nakamura, A | 1 |
| Ishizaki, T | 2 |
| Isaev, VA | 1 |
| Annese, V | 1 |
| Prada, A | 1 |
| Zambelli, A | 1 |
| Nardini, P | 1 |
| Bianchi Porro, G | 1 |
| Caos, A | 2 |
| Breiter, J | 2 |
| Perdomo, C | 6 |
| Barth, J | 4 |
| Dickman, R | 1 |
| Emmons, S | 1 |
| Cui, H | 1 |
| Sewell, J | 1 |
| Hernández, D | 1 |
| Esquivel, RF | 1 |
| Wani, S | 1 |
| Sampliner, RE | 1 |
| Weston, AP | 1 |
| Mathur, S | 1 |
| Hall, M | 1 |
| Higbee, A | 1 |
| Sharma, P | 1 |
| Oda, K | 1 |
| Hara, M | 1 |
| Danjo, A | 1 |
| Shimoda, R | 1 |
| Kikkawa, A | 1 |
| Ootani, A | 1 |
| Sakata, H | 1 |
| Tsunada, S | 1 |
| Remák, E | 1 |
| Brown, RE | 1 |
| Yuen, C | 1 |
| Robinson, A | 1 |
| Mao, L | 1 |
| Shikiar, R | 1 |
| Flood, E | 1 |
| Howell, J | 1 |
| Dodd, SL | 1 |
| Pandolfino, JE | 1 |
| Zhu, YL | 1 |
| Sun, J | 1 |
| Zha, H | 1 |
| Park, SH | 1 |
| Barer, GM | 1 |
| Pustovoĭt, EV | 1 |
| Polikanova, EN | 1 |
| Burkov, SG | 2 |
| Gurenev, GL | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Young, W | 2 |
| DeVault, KR | 1 |
| Gunaratnam, NT | 1 |
| Jessup, TP | 1 |
| Inadomi, J | 1 |
| Lascewski, DP | 1 |
| des Varannes, SB | 1 |
| Sacher-Huvelin, S | 1 |
| Vavasseur, F | 1 |
| Masliah, C | 1 |
| Le Rhun, M | 1 |
| Aygalenq, P | 1 |
| Bonnot-Marlier, S | 1 |
| Lequeux, Y | 1 |
| Galmiche, JP | 2 |
| Moriwaki, M | 1 |
| Xu, J | 1 |
| Tazuma, S | 1 |
| Inoue, M | 1 |
| Giannini, EG | 1 |
| Testa, R | 1 |
| Rodriguez-Stanley, S | 2 |
| Bemben, D | 1 |
| Zubaidi, S | 1 |
| Redinger, N | 1 |
| Kennerly, P | 1 |
| Ravic, M | 1 |
| de Boer, W | 1 |
| de Wit, N | 1 |
| Smout, A | 1 |
| Tytgat, G | 1 |
| Warrington, S | 1 |
| Baisley, K | 1 |
| Lee, D | 1 |
| Lomax, K | 2 |
| Boyce, M | 1 |
| Wertheimer, AI | 1 |
| Wilson, JM | 1 |
| Coté, GA | 1 |
| Ferreira, MR | 1 |
| Rozenberg-Ben-Dror, K | 1 |
| Nikol'skaia, KA | 1 |
| Kawamura, O | 1 |
| Maeda, M | 1 |
| Kuribayashi, S | 1 |
| Nagoshi, A | 1 |
| Zai, H | 1 |
| Moki, F | 1 |
| Horikoshi, T | 1 |
| Toki, M | 1 |
| Sugimoto, S | 1 |
| Mori, M | 1 |
| Lu, M | 1 |
| Malladi, V | 1 |
| Agha, A | 1 |
| Abudayyeh, S | 1 |
| Han, C | 1 |
| Siepman, N | 1 |
| Graham, DY | 1 |
| Yamamuro, Y | 1 |
| Yanagi, E | 1 |
| Niwa, Y | 1 |
| Iurenev, GL | 1 |
| V'iuchnova, ES | 1 |
| Sasaki, M | 1 |
| Lee, YC | 1 |
| Lin, JT | 1 |
| Wang, HP | 1 |
| Chiu, HM | 1 |
| Wu, MS | 1 |
| Fan, YH | 1 |
| Zhan, LX | 1 |
| Pai, V | 2 |
| Pai, N | 2 |
| Thibeault, SL | 1 |
| Smith, ME | 1 |
| Peterson, K | 1 |
| Ylitalo-Moller, R | 1 |
| Yamano, HO | 1 |
| Matsushita, HO | 1 |
| Yanagiwara, S | 1 |
| Shaheen, NJ | 1 |
| Madanick, RD | 1 |
| Alattar, M | 1 |
| Morgan, DR | 1 |
| Davis, PH | 1 |
| Galanko, JA | 1 |
| Spacek, MB | 1 |
| Vaughn, BV | 1 |
| James, L | 1 |
| Walson, P | 1 |
| Varughese, S | 1 |
| Reyes, J | 1 |
| Okuyama, M | 1 |
| Motoyama, S | 1 |
| Maruyama, K | 1 |
| Sasaki, K | 1 |
| Sato, Y | 1 |
| Ogawa, J | 1 |
| Morgan, DG | 1 |
| O'Mahony, MF | 1 |
| O'Mahony, WF | 1 |
| Roy, J | 1 |
| Camacho, F | 1 |
| Dinniwell, J | 1 |
| Horbay, GL | 1 |
| Husein-Bhabha, FA | 1 |
| Nojkov, B | 1 |
| Rubenstein, JH | 1 |
| Adlis, SA | 1 |
| Shaw, MJ | 1 |
| Saad, R | 1 |
| Rai, J | 1 |
| Weinman, B | 1 |
| Chey, WD | 1 |
| Kim, S | 1 |
| Zhou, Q | 1 |
| Yan, XF | 1 |
| Pan, WS | 1 |
| Zeng, S | 1 |
| Yamaguchi, K | 1 |
| Gerson, LB | 1 |
| Triadafilopoulos, G | 1 |
| Sahbaie, P | 1 |
| Mouly, S | 1 |
| Charlemagne, A | 1 |
| Le Jeunne, P | 1 |
| Fagnani, F | 1 |
| Cloud, ML | 1 |
| Enas, N | 1 |
| Bassion, S | 1 |
| Dekkers, CP | 1 |
| Beker, JA | 1 |
| Gabryelewicz, A | 1 |
| Bell, NE | 1 |
| Langtry, HD | 1 |
| Markham, A | 1 |
| Miller, JL | 1 |
| Johnson, D | 1 |
| Farley, A | 1 |
| Wruble, LD | 1 |
| Birbara, C | 1 |
| Hahne, W | 1 |
| Thomson, AB | 1 |
| Moskovitz, M | 1 |
| Dayal, Y | 1 |
| Niecestro, R | 2 |
| Ofman, JJ | 1 |
| Yamashita, BD | 1 |
| Siddique, RM | 1 |
| Larson, LR | 1 |
| Willian, MK | 1 |
| Gregor, JC | 1 |
| Delchier, JC | 1 |
| Cohen, G | 1 |
| Lanza, F | 1 |
| Bardou, M | 1 |
| Belafsky, PC | 1 |
| Postma, GN | 1 |
| Koufman, JA | 1 |
| Caro, JJ | 1 |
| Salas, M | 1 |
| Ward, A | 1 |
| Zerbib, F | 1 |
| Fournet, J | 1 |
| Rampal, P | 1 |
| Avasthy, N | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Barnett, JL | 1 |
| Carswell, CI | 1 |
| Goa, KL | 1 |
| Fitzgerald, S | 1 |
| Hegedus, R | 1 |
| Hahne, WF | 1 |
| Barth, JA | 1 |
| Metz, M | 1 |
| Loeffler, V | 1 |
| Blum, AL | 1 |
| Louis, E | 1 |
| Orr, W | 1 |
| Filippone, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Response of High-dose and Standard-dose Rabeprazole for Gastroesophageal Reflux Disease With Extra-esophageal Manifestations: a Single-center, Randomized, Open-label Trial.[NCT04001400] | Phase 3 | 73 participants (Actual) | Interventional | 2012-10-10 | Completed | ||
| A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients[NCT02135107] | Phase 3 | 517 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects With GERD 1 to 11 Months Old, Inclusive[NCT00747526] | Phase 1 | 51 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Dis[NCT00992589] | Phase 3 | 344 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Multi-Center, Double-Blind, Parallel-Group Study to Evaluate Short-term Safety and Efficacy and Long-Term Maintenance of Two Dose Levels of Rabeprazole Sodium Delayed-Release Pediatric Bead Formulation in 1- to 11-Year Old Pediatric Subjects With Endosc[NCT00787891] | Phase 3 | 127 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Effectiveness of Manual Therapy in the Treatment of Gastroesophageal Reflux Disease in Patients With Type I Hiatal Hernia[NCT05283447] | 44 participants (Actual) | Interventional | 2018-11-15 | Active, not recruiting | |||
| The Rabeprazole and Esomeprazole Reflux Assessment Trial (TREAT)[NCT00464308] | Phase 4 | 1,392 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn[NCT00237367] | Phase 4 | 52 participants (Actual) | Interventional | Completed | |||
| A Double-Blind, Placebo-Controlled Study of Rabeprazole 20 mg Maintenance Intermittent Therapy Following Acute Treatment in Patients Wth Symptomatic Gastroesophageal Reflux Disease[NCT00165841] | Phase 2 | 200 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)[NCT04149470] | Phase 4 | 90 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| Clinical Study on the Effects of the Product Mucosave® on Gastrointestinal Discomfort and the Quality of Life in Healthy Volunteers[NCT04119817] | 100 participants (Actual) | Interventional | 2019-02-09 | Completed | |||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| "Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392] | Phase 3 | 422 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD)[NCT00674245] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788] | Phase 2/Phase 3 | 144 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion[NCT00546117] | 16 participants (Actual) | Interventional | 2007-10-31 | Completed | |||
| Identification of Molecular Markers of Inflammatory Mediators in Posterior Laryngitis Due to Laryngopharyngeal Reflux and Evolution With PPI Treatment[NCT00204698] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| A Prospective Evaluation of the Utility, Optimal Cutoff and Positive Predictive Value of a Pharyngeal pH Probe for Predicting Proton Pump Inhibitor Response in Treatment Naive Laryngopharyngeal Reflux[NCT01755221] | 80 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | |||
| Physiology of GERD and Treatment Response[NCT04292470] | 7 participants (Actual) | Interventional | 2020-11-05 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Non-recurrence rate at Week 52 was estimated using the Kaplan-Meier method. (NCT02135107)
Timeframe: Week 52
| Intervention | Percentage of non-recurrence (Number) |
|---|---|
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 41.5 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 71.4 |
A comparison of rabeprazole 10 mg once daily group and the rabeprazole 10 mg twice daily group shall be performed for participants who did not exhibit daytime or nighttime heartburn at 0 weeks of the maintenance therapy period. Daytime and nighttime heartburn, and nighttime sleep disorders shall likewise be compared. For the participants who had recurrence, values at the final evaluation were imputed using a last observation carried forward (LOCF) method. (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 0 Days (no symptoms) | 1 to 2 Days (occasional symptoms) | 3 to 4 Days (sometimes had symptoms) | 5 to 6 Days (often had symptoms) | 7 Days (always had symptoms) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 85.2 | 12.3 | 1.9 | 0.0 | 0.6 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 85.1 | 11.2 | 0.6 | 1.9 | 1.2 |
Sleep disorders were defined as the condition of lack of dead sleep and arousal during sleep arising from heartburn or acid reflux. Evaluation of sleep disorders arising from heartburn or acid reflux included recording if sleep-inducing drugs were being taken before enrollment; their type, method of use, and dosage. It was requested that no changes in sleep-inducing drug be made after enrollment. Sleep disorders were rated from 0-day (no) to 7-day (always). Heartburn was evaluated prior to 7 days of each visit. (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| 0 Day (none) | 1 to 2 Days (occasional symptoms) | 3 to 4 Days (sometimes had symptoms) | 5 to 6 Days (often had symptoms) | 7 Days (always had symptoms) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 96.9 | 2.5 | 0.6 | 0.0 | 0.0 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 98.1 | 0.6 | 0.0 | 0.6 | 0.6 |
Safety was assessed by monitoring and recording all adverse events (AEs) and SAEs, regular monitoring of hematology, clinical chemistry, urine values, and regular measurement of vital signs. All AEs were graded on a 3-point scale; 1) mild was defined as discomfort that did not interfere with normal daily activities, 2) moderate was defined as discomfort that interfered with normal activities, and 3) severe was defined as discomfort that interfered with the ability to work or normal daily activities were impossible. SAEs were medical events that led to death, were life-threatening, required hospitalization or prolongation of hospitalization, caused persistent disability, or resulted in a congenital abnormality. TEAEs were AEs with an onset date on or after the first dose of study drug and up to 30 days after receiving the last dose of study drug. Treatment-related AEs were medical events that were considered by the investigator to be possibly or probably related to rabeprazole. (NCT02135107)
Timeframe: From date of first dose up to 30 days after the last dose of study drug, up to approximately 1 year 3 months (Treatment Period; 8 weeks, Maintenance Therapy Period; 52 weeks, and Follow-up Period; 30 days)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| TEAEs | Treatment-related TEAEs | Severe TEAEs | Serious TEAEs | |
| Rabeprazole: 10 mg Twice Daily | 111 | 20 | 2 | 6 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once daiArm C | 111 | 7 | 4 | 11 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 125 | 11 | 3 | 17 |
| Rabeprazole: 20 mg Twice Daily | 21 | 1 | 1 | 4 |
A comparison of the rabeprazole 10 mg once daily group and the rabeprazole 10 mg twice daily group was performed for participants who did not exhibit daytime or nighttime heartburn at Week 0 of the Maintenance Therapy Period. Heartburn is a burning sensation in the stomach or lower chest; it is worsened by bending or pressure on the abdomen. Heartburn frequency was rated from 0-day (no) to 7-day (always) and severity was graded on a 3-point scale (mild, moderate, severe). Heartburn was evaluated in the daytime (from wake-up time to time for bed) and nighttime (from time for bed to wake-up time). (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Heartburn (yes) | Heartburn (no) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 23.2 | 76.8 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 8.0 | 92.0 |
"Sleep disorders were defined as the condition of lack of dead sleep and arousal during sleep arising from heartburn or acid reflux. Sleep disorders during each of the 7-day periods immediately before visiting the hospital were assessed. Evaluation of sleep disorders arising from heartburn or acid reflux included recording if sleep-inducing drugs were being taken before enrollment; their type, method of use, and dosage. It was requested that no changes in sleep-inducing drug be made after enrollment. Sleep disorders were rated from 0-day (no) to 7-day (always). The incidence of sleep disorder was tabulated by an analysis classifying the stages into two groups: No (0 days with sleep disorder) and Yes (1 or more days with sleep disorder). Heartburn was evaluated prior to 7 days of each visit." (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Sleep disorders from heartburn/acid reflux (yes) | Sleep disorders from heartburn/acid reflux (no) | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 2.5 | 97.5 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 2.5 | 97.5 |
The non-recurrence rate (at 52 weeks) was determined by the endoscopy central review panel who were blinded to the investigator's assessment, based on the modified Los Angeles Classification using endoscopy photos were submitted by each of the institutions. Participants showing Grade A or above based on the modified Los Angeles Classification were included as a recurrence. (NCT02135107)
Timeframe: Week 52
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Non-recurrence | Recurrence | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 44.8 | 55.2 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 73.9 | 26.1 |
The non-recurrence rate (up to 52 weeks) was determined by the endoscopy central review panel who were blinded to the investigator's assessment, based on the modified Los Angeles Classification using endoscopy photos were submitted by each of the institutions. Participants showing Grade A or above based on the modified Los Angeles Classification were included as a recurrence. The 95% CI was calculated by normal approximation. (NCT02135107)
Timeframe: Weeks 12 and 24
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| Week 12, Non-recurrence | Week 12, Recurrence | Week 24, Non-recurrence | Week 24, Recurrence | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 62.5 | 37.5 | 55.8 | 44.2 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 92.4 | 7.6 | 85.1 | 14.9 |
"A comparison of the rabeprazole (10 mg once daily group) and the rabeprazole (10 mg twice daily group) was performed for participants who did not exhibit daytime or nighttime heartburn at Week 0 of the Maintenance Therapy Period. The presence or absence of heartburn was assessed by the investigators during medical interviews. The heartburn incidence during each of the 7-day periods immediately before visiting the hospital was assessed on a scale of five stages based on the number of days with symptoms: 0 (no symptoms), 1 to 2 (occasional symptoms), 3 to 4 (sometimes had symptoms), 5 to 6 (often had symptoms), and 7 (always had symptoms). The incidence was tabulated by an analysis classifying the states into two groups: no symptom group (0 days with symptoms) and with symptoms group (1 day or more with symptoms). The severity of heartburn was as below: Mild (feel heartburn but tolerable), Moderate (feel heartburn and hard), and Severe (feel heartburn and terrible)." (NCT02135107)
Timeframe: From Week 4 up to Week 52
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| None | Mild | Moderate | Severe | |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Once Daily | 85.2 | 14.8 | 0.0 | 0.0 |
| Rabeprazole: 10 or 20 mg Twice Daily, Then 10 mg Twice Daily | 85.1 | 14.3 | 0.6 | 0.0 |
(NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | frequency of Regurgitation (Mean) |
|---|---|
| Double-Blind Placebo | -0.8 |
| Double-Blind Rabeprazole Sodium 5 mg | -0.8 |
| Double-Blind Rabeprazole Sodium 10 mg | -1.6 |
| Double-Blind Rabeprazole Sodium Total | -1.2 |
The Infant Gastroesophageal Reflux Questionnaire-Revised (I-GERQ-R) is a 12-item questionnaire that is completed by the primary caregiver at every office or telephonic visit. It has a weekly recall and the items cover the frequency, amount and discomfort attributed to spit-up, refusal or stopping feeding, crying and fussing, hiccups, arching back and stopping breathing or changing color. The total score is calculated as the sum of all 12 scores for the individual questions, and ranges from 0 to 42. A higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | scores on a scale (Mean) |
|---|---|
| Double-Blind Placebo | -3.6 |
| Double-Blind Rabeprazole Sodium 5 mg | -3.8 |
| Double-Blind Rabeprazole Sodium 10 mg | -4.1 |
| Double-Blind Rabeprazole Sodium Total | -3.9 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. Each of the 9 items will be assigned a numeric score. The total score will be calculated as the sum of all 9 items, and ranges from 0 to 37. A higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | scores on a scale (Mean) |
|---|---|
| Double-Blind Placebo | -1.9 |
| Double-Blind Rabeprazole Sodium 5 mg | -1.6 |
| Double-Blind Rabeprazole Sodium 10 mg | -2.1 |
| Double-Blind Rabeprazole Sodium Total | -1.9 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Discomfort subscale score will be calculated as the sum of the 3 questions regarding discomfort (Questions, 7, 8, 9) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | scores on a scale (Mean) |
|---|---|
| Double-Blind Placebo | 0.0 |
| Double-Blind Rabeprazole Sodium 5 mg | -0.1 |
| Double-Blind Rabeprazole Sodium 10 mg | -0.4 |
| Double-Blind Rabeprazole Sodium Total | -0.2 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the subject has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Eating Behavior subscale score will be calculated as the sum of the 3 questions regarding eating behavior (Questions 4, 5, 6) and will range from 0 to 12. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | scores on a scale (Mean) |
|---|---|
| Double-Blind Placebo | -0.1 |
| Double-Blind Rabeprazole Sodium 5 mg | -0.1 |
| Double-Blind Rabeprazole Sodium 10 mg | -0.4 |
| Double-Blind Rabeprazole Sodium Total | -0.3 |
The Infant Gastroesophageal Reflux Questionnaire-Daily Diary (I-GERQ-DD) is a 9-item daily diary that the primary caregiver will be instructed to complete every evening at the same time interval after the participant has gone to sleep for the night. The I-GERQ-DD contains 3 subscales: the Regurgitation subscale, the Eating Behavior subscale and the Discomfort subscale. The Regurgitation subscale will be calculated as the sum of the 3 questions regarding regurgitation (Questions 1, 2, 3) and will range from 0 to 13. For each subscale score, a higher value indicates a worse outcome. (NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | scores on a scale (Mean) |
|---|---|
| Double-Blind Placebo | -0.8 |
| Double-Blind Rabeprazole Sodium 5 mg | -0.8 |
| Double-Blind Rabeprazole Sodium 10 mg | -1.0 |
| Double-Blind Rabeprazole Sodium Total | -0.9 |
Body weight was measured with the participant unclothed and before a feeding during each office visit. In the analysis of weight data, weight will be transformed to the weight-for-age Z-score using World Health Organization Child Growth Standards, taking into account the infant's age and gender (Borghi E, 2006). (NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | Z-score (Mean) |
|---|---|
| Double-Blind Placebo | 0.11 |
| Double-Blind Rabeprazole Sodium 5 mg | 0.16 |
| Double-Blind Rabeprazole Sodium 10 mg | 0.11 |
| Double-Blind Rabeprazole Sodium Total | 0.14 |
(NCT00992589)
Timeframe: Baseline, Week 8
| Intervention | number of episodes (Mean) | ||||
|---|---|---|---|---|---|
| Less than 1 tablespoon | 1 to 2 tablespoons | More than 2 tablespoons to 2 fluid oz | More than 2 fluid oz to 4 fluid oz | More than 4 fluid oz | |
| Double-Blind Placebo - Baseline | 1.2 | 0.7 | 0.3 | 0.1 | 0.0 |
| Double-Blind Placebo - Week 8 | 0.8 | 0.5 | 0.2 | 0.0 | 0.0 |
| Double-Blind Rabeprazole Sodium 10 mg - Baseline | 1.9 | 1.2 | 0.3 | 0.0 | 0.0 |
| Double-Blind Rabeprazole Sodium 10 mg - Week 8 | 1.0 | 0.7 | 0.2 | 0.0 | 0.0 |
| Double-Blind Rabeprazole Sodium 5 mg - Baseline | 1.1 | 0.7 | 0.2 | 0.0 | 0.0 |
| Double-Blind Rabeprazole Sodium 5 mg - Week 8 | 0.7 | 0.4 | 0.1 | 0.0 | 0.0 |
| Double-Blind Rabeprazole Sodium Total - Baseline | 1.5 | 1.0 | 0.2 | 0.0 | 0.0 |
| Double-Blind Rabeprazole Sodium Total - Week 8 | 0.9 | 0.6 | 0.2 | 0.0 | 0.0 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 36
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 0.2 |
| Rabeprazole Sodium 1.0 mg/kg | 0.2 |
The Hetzel and Dent Classification grades range from 0 (normal esophageal mucosa, no abnormalities noted) to 4 (deep ulcers anywhere in the esophagus or ulceration of more than half of the esophageal mucosa). Higher observed scores indicate more serious condition. For change of baseline, a score of 0 indicates no change; a positive score indicates the condition is worsening, while a negative score indicates an improvement. (NCT00787891)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -1.3 |
| Rabeprazole Sodium 1.0 mg/kg | -1.0 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 36
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -2.9 |
| Rabeprazole Sodium 1.0 mg/kg | -1.4 |
The gastroesophageal reflux disease (GERD) symptom and severity scale measures the frequency (0= Never; 1= 1-2 times; 2= 3-4 times; 3= 5-6 times; 4= 7 or more times) and the severity (1= Mild; 2= Moderate; 3=Severe) of GERD symptoms. The score is defined as the sum of the frequency (0-4) and severity (1-3) of that symptom. The total score is the sum of the scores of all the symptoms and ranges from 12 to 84. Higher scores indicate more serious condition. For change from baseline, 0 indicates no change; a positive score indicates worsening, while a negative score indicates improvement. (NCT00787891)
Timeframe: Baseline, Week 12
| Intervention | Scores on a scale (Mean) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | -11.5 |
| Rabeprazole Sodium 1.0 mg/kg | -8.5 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 78 |
| Rabeprazole Sodium 1.0 mg/kg | 83 |
Healing is defined as macroscopically normal esophageal mucosa or histologic normal esophageal mucosa. (NCT00787891)
Timeframe: 36 weeks
| Intervention | Percentage of patients (Number) |
|---|---|
| Rabeprazole Sodium 0.5 mg/kg | 92 |
| Rabeprazole Sodium 1.0 mg/kg | 88 |
(NCT00464308)
Timeframe: 4 weeks
| Intervention | percent of participants (Mean) |
|---|---|
| Rabeprazole 20 mg/Day | 56.3 |
| Esomeprazole 40 mg/Day | 63.4 |
| Esomeprazole 20 mg/Day | 56.1 |
(NCT00464308)
Timeframe: 4 weeks
| Intervention | days (Median) |
|---|---|
| Rabeprazole 20 mg/Day | 9 |
| Esomeprazole 40 mg/Day | 11 |
| Esomeprazole 20 mg/Day | 13 |
(NCT00464308)
Timeframe: week 4 of treatment
| Intervention | days (Median) |
|---|---|
| Rabeprazole 20 mg/Day | 11 |
| Esomeprazole 40 mg/Day | 9 |
| Esomeprazole 20 mg/Day | 12 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 281 |
| Esomeprazole 40 mg/Day | 283 |
| Esomeprazole 20 mg/Day | 276 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild) assessed by the PAGI-SYM scale. This likert scale describes various symptoms as follows: 0-none, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5-Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 405 |
| Esomeprazole 40 mg/Day | 418 |
| Esomeprazole 20 mg/Day | 414 |
Satisfactory resolution, which is achieved if, on any 7 consecutive days within the 4 week period, the severity of symptoms never exceeds 'mild' (symptoms must be absent, very mild, or mild)assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: 4 weeks
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 397 |
| Esomeprazole 40 mg/Day | 413 |
| Esomeprazole 20 mg/Day | 402 |
Complete resolution is the absence of symptoms for any 7 consecutive days within the 4 week period assessed by the PAGI-SYM scale. This likert scale describes a series of symptoms as follows: 0-None, 1-Very Mild, 2-Mild, 3-Moderate, 4-Severe, 5 Very Severe. (NCT00464308)
Timeframe: week 4 of treatment
| Intervention | participants (Number) |
|---|---|
| Rabeprazole 20 mg/Day | 272 |
| Esomeprazole 40 mg/Day | 302 |
| Esomeprazole 20 mg/Day | 278 |
The percentage of heartburn-free days during the 6-month Maintenance Treatment Phase in patients treated with rabeprazole 20 mg compared to patients who received placebo in the ITT Population. Heartburn-free day was defined as no heartburn in both the daytime and nighttime period on a given day. Note a total 388 subjects were enrolled at the beginning of Acute Phase and 200 subjects were enrolled into the double-blind 6-month maintenance treatment phase. (NCT00165841)
Timeframe: 6 months double-blind maintenance phase
| Intervention | Percentage of Days (Mean) |
|---|---|
| Rabeprazole 20 mg | 82.58 |
| Placebo | 62.17 |
(NCT00546117)
Timeframe: 2 months
| Intervention | participants (Number) |
|---|---|
| Prevacid | 1 |
| Placebo | 3 |
(NCT00546117)
Timeframe: 2 months
| Intervention | participants (Number) |
|---|---|
| Prevacid | 1 |
| Placebo | 0 |
Spectral gradient acoustic reflectometry is a noninvasive, non-audible acoustic wave used to help detect middle ear fluid. The manufacturer recommends interpretation of the angle result as: <49°, high risk of middle ear effusion (level 5); 49-59°, moderate-high risk (level 4); 60-69°, moderate risk (level 3); 70-95°, low-moderate risk (level 2) and >95°, low risk (level 1). (NCT00546117)
Timeframe: 2 months
| Intervention | level of risk (Mean) |
|---|---|
| Lansoprazole (Prevacid) | 2.5 |
| Placebo | 3.5 |
Questions regarding reflux symptoms, created and evaluated by Nelson et al, Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey, Arch Pediatr Adolesc Med 2000;154;150-154. This study used the GER3-9P version for children aged 3-9 years. Results are reported as number reporting at least one specific symptom in the past week, maximum 7 symptoms. (NCT00546117)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Lansoprazole (Prevacid) | 0 |
| Placebo | 0 |
"Tympanometry of both ears, coded by Jerger classification (Type A, normal; type B, flat; Type C; negative pressure).~This is a standard test of middle ear status as performed by audiologists. Please refer to the reference for more information: Kileny & Zwolan, Diagnostic Audiology, chapter 133, Cummings Otolaryngology-Head and Neck Surgery, Elsevier/Saunders, 2015." (NCT00546117)
Timeframe: 2 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Lansoprazole (Prevacid) | 0 |
| Placebo | 0 |
Change in the average daily GERD symptom severity score over a 7-day period from baseline to the last week of the study in the expanded vs. standard group. GERD symptom severity is based on the sum of scores assessing the severity of daytime heartburn, nighttime heartburn, and acid reflux each on a 0-4 point scale (none, mild, moderate, severe, very severe; higher scores signify worse symptoms). Possible score range = 0 - 12. Change score calculated as average score at 8 weeks minus average score at baseline. For statistical testing, we used a general linear model of post-GERD symptoms adjusted for baseline GERD symptoms and randomization assignment. (NCT04292470)
Timeframe: Time 0 (baseline) to 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Standard Visit | 0.6 |
| Expanded Visit | -1.7 |
Concordance in skin conductance response (SCR) between patient and physician was calculated using an established approach to create a single index value for the visit (baseline). Average slopes of the SCR were calculated in moving 5 second windows, offset by 1 second. Pearson correlations between time-locked patient and physician SCR slopes were calculated over successive 15 second windows. A single session index was calculated from the ratio of the sum of the positive correlations across the entire visit divided by the sum of the absolute value of the negative correlations across the entire visit. To reduce skew, the natural logarithm of the index was calculated. An index value of zero reflects equal positive and negative correlations, a value greater than zero reflects more concordance in SCR than not, while a value less than zero reflects less than 50% concordance. In the statistical analysis, we included change in GERD symptoms from baseline to 8 weeks. (NCT04292470)
Timeframe: Time 0 (baseline) to 8 weeks.
| Intervention | natural log of the index value (Mean) |
|---|---|
| Standard Visit | 0.02 |
| Expanded Visit | -2.2 |
43 reviews available for rabeprazole and Esophageal Reflux
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Topics: Adult; Bayes Theorem; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Network Meta-Analysis | 2022 |
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointes | 2023 |
Pharmacological treatment of gastro-oesophageal reflux in children.
Topics: Adolescent; Child; Esomeprazole; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Omeprazol | 2023 |
Rabeprazole 10 mg versus 20 mg in preventing relapse of gastroesophageal reflux disease: a meta-analysis.
Topics: Dose-Response Relationship, Drug; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Rabeprazo | 2013 |
The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis.
Topics: Anti-Ulcer Agents; Esophagitis, Peptic; Gastroesophageal Reflux; Humans; Omeprazole; Proton Pump Inh | 2016 |
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopi | 2017 |
Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Topics: Animals; Drug Interactions; Gastroesophageal Reflux; Humans; Peptic Ulcer; Proton Pump Inhibitors; R | 2018 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Gastric Acid; Gastroesophagea | 2009 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
Rabeprazole for the treatment of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Enzyme Inhibitors; Gastroesophageal Refl | 2012 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esop | 2013 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, | 2002 |
Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; | 2003 |
[Modern approach to the therapy of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2003 |
Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cytochrome P-450 Enzyme | 2004 |
[Primary care for GEDR].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Circadian Rhythm; Drug Therapy, Combination | 2004 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combin | 2004 |
[PPI: new strategies for GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Ci | 2004 |
Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2004 |
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastric Aci | 2004 |
Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastric Ac | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph | 2004 |
Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastroesop | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocar | 2005 |
CYP2C19 genotype and the PPIs--focus on rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Aryl Hydrocar | 2005 |
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys | 2006 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransf | 2007 |
Recent advances in chirally pure proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esomeprazole; Gastroesophageal Reflux; Humans; Isomerism; O | 2007 |
Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 1999 |
The benefit/risk profile of rabeprazole, a new proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Controlled Clinical Trials as Topic; Duoden | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Efficacy of rabeprazole once daily for acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazole | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cytochrome P | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
Rabeprazole: an update of its use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2001 |
111 trials available for rabeprazole and Esophageal Reflux
| Article | Year |
|---|---|
Protocol of a randomized, double-blind, placebo-controlled study of the effect of probiotics on the gut microbiome of patients with gastro-oesophageal reflux disease treated with rabeprazole.
Topics: Double-Blind Method; Gastroesophageal Reflux; Gastrointestinal Microbiome; Humans; Probiotics; Proto | 2022 |
Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.
Topics: Esomeprazole; Gastroesophageal Reflux; Humans; Prospective Studies; Rabeprazole; Treatment Outcome | 2022 |
Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Cross-Sectional Studies; Drug Therapy, Combin | 2020 |
Efficacy of a high-dose proton pump inhibitor in patients with gastroesophageal reflux disease: a single center, randomized, open-label trial.
Topics: Gastroesophageal Reflux; Heartburn; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2020 |
Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Topics: Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 2018 |
Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study.
Topics: Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Endosco | 2018 |
Efficacy and safety of hangeshashinto for treatment of GERD refractory to proton pump inhibitors : Usual dose proton pump inhibitors plus hangeshashinto versus double-dose proton pump inhibitors: randomized, multicenter open label exploratory study.
Topics: Adult; Aged; Drug Therapy, Combination; Drugs, Chinese Herbal; Dyspepsia; Female; Gastroesophageal R | 2019 |
Combined pH-impedance monitoring and high-resolution manometry of Japanese patients treated with proton-pump inhibitors for persistent symptoms of non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Asian People; Esophagoscopy | 2012 |
Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old.
Topics: Gastrins; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Proton | 2013 |
Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old.
Topics: Gastrins; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Proton | 2013 |
Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old.
Topics: Gastrins; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Proton | 2013 |
Normal and proton pump inhibitor-mediated gastrin levels in infants 1 to 11 months old.
Topics: Gastrins; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Infant; Infant, Newborn; Proton | 2013 |
Efficacy and safety of rabeprazole in children (1-11 years) with gastroesophageal reflux disease.
Topics: Abdominal Pain; Body Weight; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Es | 2013 |
On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2013 |
Sleep disturbances and refractory gastroesophageal reflux disease symptoms in patients receiving once-daily proton pump inhibitors and efficacy of twice-daily rabeprazole treatment.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton P | 2013 |
Safety and efficacy of delayed release rabeprazole in 1- to 11-month-old infants with symptomatic GERD.
Topics: Body Weight; Double-Blind Method; Gastroesophageal Reflux; Humans; Infant; Infant, Newborn; Male; Pr | 2014 |
Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD.
Topics: Abdominal Pain; Child; Child, Preschool; Diarrhea; Double-Blind Method; Endoscopy, Gastrointestinal; | 2014 |
Clinical characteristics of elderly patients with proton pump inhibitor-refractory non-erosive reflux disease from the G-PRIDE study who responded to rikkunshito.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Drugs, Chinese Herbal; Female; Gastric Emptying; Gastr | 2014 |
Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anxiety; Cytochrome P-450 CYP2C19; Depression; Dos | 2015 |
Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Female; Gastroesopha | 2015 |
Short-term and long-term effect of diaphragm biofeedback training in gastroesophageal reflux disease: an open-label, pilot, randomized trial.
Topics: Biofeedback, Psychology; Combined Modality Therapy; Diaphragm; Esophageal pH Monitoring; Esophagogas | 2016 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double | 2016 |
Ten mg dexrabeprazole daily is as effective as 20 mg rabeprazole daily.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2008 |
The role of gastroesophageal reflux in exercise-triggered asthma: a randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Asthma, Exercise-Induced; Double-Blind Method; Esoph | 2009 |
Rabeprazole plus domperidone: the answer for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Domperidone; Dopamine Antagonists | 2008 |
Non-cardiac chest pain: prevalence of reflux disease and response to acid suppression in an Asian population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Asian People; Chest Pain; Endoscopy, Digestive | 2009 |
Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care--prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2009 |
Rabeto plus: a valuable drug for managing functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzamides; Benzyl Compounds; Drug | 2008 |
Comparison of one-week and two-week empirical trial with a high-dose rabeprazole in non-cardiac chest pain patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Chest Pain; Drug Administration Schedule; Empi | 2009 |
A postmarketing surveillance study of dexrabeprazole in the treatment of acid peptic disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; | 2009 |
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Inflammatory Agents, Non-Steroid | 2010 |
The effect of acid suppression on upper airway anatomy and obstruction in patients with sleep apnea and gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Comorbidity; Female; Gastroesopha | 2009 |
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2010 |
Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2010 |
[Long-term impact on quality of life in patients with gastroesophageal reflux disease after 52-week rabeprazole treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Follow-Up Studies; | 2009 |
Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, | 2011 |
Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Dose-Response Relationship, Dru | 2011 |
Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; | 2011 |
Pharmacokinetics and tolerability of rabeprazole in children 1 to 11 years old with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Area Under Curve; Body Weight; Child; Child, P | 2011 |
Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research G
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2011 |
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P | 2011 |
Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Body Mass Index; Dose-Respo | 2012 |
Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Chi-Square Distribution; Esophageal pH M | 2012 |
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female; | 2012 |
A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Heartburn; Histamin | 2012 |
[Clinical effects of dalitong granule combined proton pump inhibitors on gastroesophageal reflux disease].
Topics: Adolescent; Adult; Aged; Drugs, Chinese Herbal; Female; Gastroesophageal Reflux; Humans; Integrative | 2012 |
Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Re | 2013 |
Histology of symptomatic gastroesophageal reflux disease: is it predictive of response to proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Bioma | 2013 |
Clinical symptoms of FSSG in gastroesophageal reflux disease are critical for PPI treatment: Japanese multi-centers with 185 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; H | 2012 |
Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Female; Gastroe | 2002 |
Patients have treatment preferences: a multicentre, double-blind, crossover study comparing rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chi-Square | 2002 |
A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Dose-Respon | 2003 |
Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Eating; Female; G | 2003 |
Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gast | 2003 |
Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Esophagitis, Pe | 2003 |
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2003 |
Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Cross- | 2003 |
The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
[Evaluation of the efficacy of pariet in patients with gastroesophageal reflux disease with thoracic pain not connected with cardiac disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Chest Pain; Enzyme Inhibitors; Femal | 2003 |
[Comparative clinical and economic efficiency of new generation proton pump inhibitors in the treatment of gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Drug Adm | 2003 |
Association between nocturnal bruxism and gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Bruxism; Electrom | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-S | 2003 |
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2003 |
[Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Cross-Over S | 2003 |
Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Double-Blin | 2004 |
Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gas | 2004 |
On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Fema | 2004 |
Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina Pectoris; Anti-Ulcer Agents; Benzimidazoles; Comorbi | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2004 |
Significance of non-erosive minimal esophageal lesions in gastro-esophageal reflux disorder.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
[Particular features of application of proton pump inhibitors (Rabeprazole) in children with the gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Benzimidazoles; Child; Enzyme Inhibitors; Femal | 2004 |
Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chronic Disease; Double-Blind Method; Enzym | 2004 |
[Some comparative aspects of treating the gastroesophageal reflux disease eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2004 |
[Clinical and pharmacoeconomic aspects of the antisecretory therapy of gastroesophageal refluxed disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Esophagoscopy; Gastr | 2004 |
The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Female; | 2005 |
[Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenoscopy; Esophagosc | 2005 |
Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Biopsy; Dis | 2005 |
Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Benzi | 2005 |
Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Esomeprazole; F | 2005 |
[Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Enzyme Inhibitors; Female; Gas | 2005 |
Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance o
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Benzimidazoles; Dose-Re | 2005 |
Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chest Pain; | 2005 |
Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett | 2005 |
Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition Disord | 2005 |
Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Benzimidazoles; Dose-Response Relationship | 2005 |
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2006 |
Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As | 2006 |
Effect of esophageal acid and prophylactic rabeprazole on performance in runners.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagus; Exercise Test; Female; | 2006 |
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female | 2006 |
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2007 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Hu | 2007 |
Failures in a proton pump inhibitor therapeutic substitution program: lessons learned.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aluminum Hydroxide; Analysis of Variance; Cross-Over | 2007 |
[Rabeprazole test and comparison of the effectiveness of course treatment with rabeprazole in patients with gastroesophageal reflux disease and non-coronary chest pain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroe | 2007 |
Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hyd | 2007 |
[Oesophageal acid exposure test in non-erosive gastroesophageal reflux disease and the diagnostic value of rabeprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagus; Female; Gastric Acid; | 2007 |
Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2007 |
Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Analysis of Variance; Anti-Ulcer Agents; Area U | 2007 |
Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Dose-Response Relationsh | 2007 |
Response rate and predictors of response in a short-term empirical trial of high-dose rabeprazole in patients with globus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 2008 |
It is possible to classify non-erosive reflux disease (NERD) patients into endoscopically normal groups and minimal change groups by subjective symptoms and responsiveness to rabeprazole -- a report from a study with Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Endoscopy, Digestive System | 2008 |
Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Dose-Respo | 1998 |
Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1999 |
Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Benzimidazoles; D | 2000 |
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Benzimidazoles; Dose-Res | 2000 |
Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2000 |
Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Double-Blind Method; Drug Administra | 2000 |
Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Rel | 2001 |
Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Esophagitis | 2002 |
Integrated acidity and rabeprazole pharmacology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Pept | 2002 |
A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2002 |
Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Dose-Response Relationship, Drug; Do | 2002 |
91 other studies available for rabeprazole and Esophageal Reflux
| Article | Year |
|---|---|
The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoplasmic Reticulum Stress; Female; Gastroesophage | 2023 |
Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 2023 |
Reply to the letter to the editor "Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease".
Topics: Gastroesophageal Reflux; Humans; Omeprazole; Rabeprazole | 2023 |
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Topics: Computer Simulation; Cost-Benefit Analysis; Esomeprazole; Gastroesophageal Reflux; Humans; Japan; Ma | 2019 |
Measurement of low-grade inflammation of the esophageal mucosa with electrical conductivity shows promise in assessing PPI responsiveness in patients with GERD.
Topics: Animals; Caco-2 Cells; Electric Conductivity; Esophageal Mucosa; Esophageal pH Monitoring; Female; G | 2021 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female | 2018 |
Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation.
Topics: Adult; Aged; Chronic Disease; Cough; Female; Gastroesophageal Reflux; Humans; Inflammation; Leukocyt | 2020 |
Acid burn or cytokine sizzle in the pathogenesis of heartburn?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Esophagus; Female; Gastroesophageal Re | 2013 |
The effect of rabeprazole on LES tone in experimental rat model.
Topics: Animals; Carbachol; Esophageal Sphincter, Lower; Gastroesophageal Reflux; In Vitro Techniques; Muscl | 2013 |
The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Female; Gastroesophageal Reflux; Humans; Japan; | 2014 |
Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
Topics: Adolescent; Adult; Biological Availability; Child; Child, Preschool; Clinical Trials, Phase I as Top | 2014 |
Iron-deficiency anemia caused by a proton pump inhibitor.
Topics: Anemia, Iron-Deficiency; Famotidine; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton Pump | 2014 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Ther | 2014 |
Pretreatment prediction of symptom response to proton pump inhibitor therapy.
Topics: Adult; Aged; Dyspepsia; Female; Forecasting; Gastroesophageal Reflux; Humans; Male; Middle Aged; Pro | 2015 |
Control of acid and duodenogastroesophageal reflux (DGER) in patients with Barrett's esophagus.
Topics: Aged; Barrett Esophagus; Bilirubin; Deglutition Disorders; Esophageal pH Monitoring; Female; Gastroe | 2015 |
Characteristics of symptomatic reflux episodes in Japanese proton pump inhibitor-refractory non-erosive reflux disease patients.
Topics: Adult; Aged; Asian People; Drug Administration Schedule; Drug Resistance; Electric Impedance; Esopha | 2015 |
Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors.
Topics: Electric Impedance; Esophagus; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; | 2016 |
Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Esophageal pH Monitoring; F | 2008 |
The effect of gastroesophageal flap valve appearance on the management of patients with symptoms of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Esophagogastric Junction; Female; Gastroesopha | 2009 |
Evaluation of upper abdominal symptoms using the Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease in patients with laryngopharyngeal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Enzyme Inhibitors; Esophage | 2008 |
Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Gastroesophageal Reflux; Humans; Proton | 2008 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbi | 2008 |
Reflux profile of Chinese gastroesophageal reflux disease patients with combined multichannel intraluminal impedance-pH monitoring.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Case- | 2009 |
Is longer duration of proton pump inhibitor trial better for gastroesophageal reflux disease-related non-cardiac chest pain?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Clinical Trials as Topic; Drug Administration S | 2009 |
[Combined therapy of acid-dependent gastrointestinal disorders with the use of antacidic drug Relcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; A | 2009 |
[The quality of life dynamics in patients with gastroesophageal reflux disease during rabeprazol therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Pe | 2009 |
Sleep dysfunction in Japanese patients with gastroesophageal reflux disease: prevalence, risk factors, and efficacy of rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Asian People; Female; Gastroesophageal Reflux; | 2010 |
Non-erosive reflux disease (NERD), symptomatic and asymptomatic erosive reflux disease (ERD): from hypersensitive to hyposensitive esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Case-Control Studies; Disease Progression; Fem | 2011 |
Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Dyspepsia; Esophageal Motility Disorders | 2010 |
Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Esophageal pH Monitoring; Female; Gastroesopha | 2010 |
Risk factors for relapse of erosive GERD during long-term maintenance treatment with proton pump inhibitor: a prospective multicenter study in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Body Height; Esophagus; Female; Fo | 2010 |
Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Chi-Square Distribution; Dyspepsia | 2010 |
Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bi | 2011 |
Relevance and characteristics of gastroesophageal reflux in adult patients with otitis media with effusion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Bilirubi | 2011 |
Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Esophageal Neoplasms; Gastroeso | 2011 |
Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Eosinophilic Esophagitis; Esophageal pH Monitoring; Gastroe | 2011 |
Editorial: Reflux, dyspepsia, and Rome III (or Rome IV?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophageal pH Monitoring; Esophagoscopy; Gastroe | 2010 |
Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Drug Resistance; Gast | 2011 |
The role of Acid in functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 2011 |
Response to air insufflation in patients with non-erosive gastro-oesophageal reflux disease (NERD).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Female; Gastroesop | 2011 |
Comparison of patients of chronic laryngitis with and without troublesome reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Anti-Ulcer Agents; Chronic Disease; End | 2012 |
Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Body Mass Index; Esophagitis, Pept | 2012 |
Practice pattern of gastroenterologists for the management of GERD under the minimal influence of the insurance reimbursement guideline: a multicenter prospective observational study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; | 2011 |
Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cohort Studies; Esophagitis, Pepti | 2012 |
Rabeprazole-induced acute cholestatic liver injury.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cholestasis; Gastroesophageal Reflux; Hu | 2012 |
Hypomagnesemia associated with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Humans; Magnesium; Magnesium Defic | 2012 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Child; Child, Pres | 2002 |
[Effectiveness of pariet (rabeprazole) in the treatment of gastroesophageal reflux disease (at the reflux-esophagitis stage)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2002 |
Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2002 |
A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Asthma; Benzimidazoles; Female; Ga | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databa | 2004 |
Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Brain; Diagnosis, Differential; Gast | 2003 |
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; | 2004 |
Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Circadian Rhythm; Gastri | 2004 |
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesop | 2005 |
Development and validation of the Gastroesophageal Reflux Disease Treatment Satisfaction Questionnaire.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
Four-day Bravo pH capsule monitoring with and without proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; Ca | 2005 |
[The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2005 |
[Oral cavity manifestations of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagus; Female; Follo | 2005 |
Efficacy of a proton pump inhibitor given in the early postoperative period to relieve symptoms of hiatal hernia after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Benzimidazoles; Cardiac Sur | 2006 |
The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Catheterization; Esophag | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibi | 2006 |
Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aminopyrine; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2006 |
Pharmacodynamic studies on PPIs: look carefully at the country of origin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; As | 2006 |
Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cohort Studies; Enzyme Inhibitors; Female; Gastroesophageal | 2006 |
Comparative drug effects: the case of GERD therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Disease Management; Gastroesophageal Reflux; Heal | 2007 |
Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost Sav | 2007 |
[Results of the treatment of duodenal ulcer associated with Helicobacter pylori and combined with gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
Prediction of gastroesophageal reflux in otitis media with effusion in adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Ear, Mid | 2007 |
Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; | 2007 |
Gene expression changes of inflammatory mediators in posterior laryngitis due to laryngopharyngeal reflux and evolution with PPI treatment: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Biopsy; Esophageal pH Monit | 2007 |
Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Ga | 2008 |
Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Female; Gastric | 2008 |
Proton pump inhibitors relieve and prevent symptoms related to gastric acidity after esophagectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Cohort Studies; Esophageal Stenosis; Esophagectomy; E | 2008 |
The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Female; Gastroesophageal Reflux; H | 2008 |
Is the required therapeutic effect always achieved by racemic switch of proton-pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Proton | 2008 |
Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Circadian Rhythm; Esophageal pH Monitoring; Esophagus; Gast | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomepra | 2008 |
[Proton-pump inhibitor Rabeprazole: faster acid- and symptom-control].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1998 |
Rabeprazole is latest entrant in proton-pump-inhibitor class.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Rabeprazole sodium.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Gastroes | 1999 |
Rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adenosine Triphosphatases; Anti-Ulcer Agent | 1999 |
Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Trees; Drug | 2000 |
Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Decision Support Tec | 2000 |
Treatment strategies for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cytochrome P-450 Enzyme System; Drug Intera | 2000 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Optimizing acid-suppression therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2001 |
[Pharma-clinics medication of the month. Rabeprazole (Pariet)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulcer; E | 2002 |